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Abstract 
Baseline muscle sympathetic nerve activity (MSNA) comparisons of age (young & 
old, n=40) and cardiovascular disease (CVD) state (young: Y, old: O, metabolic syndrome: 
MET, coronary artery disease: CAD, chronic heart failure: CHF, n= 36) groups were made 
to assess which MSNA variable(s) best describe group differences using a MANOVA-
based approach across 10 variables. The hypothesis that action potential (AP) variables 
would better discriminate between groups than integrated variables was not supported. 
Burst frequency and incidence together significantly differentiated between groups with 
variability attributed to spikes/min and spikes/100hb removed. Significant group 
differences were noted for these variables such that Y<O regardless of CVD state until 
CHF, increasing both values. AP variables were different only between Y<CHF. These 
findings suggest that burst incidence and frequency should be reported for baseline 
MSNA studies and work on amplitude-based measures, and reflex-mediated responses 
should be completed to further assess MSNA variable differences between groups. 
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Preface 
A primary function of the sympathetic nervous system is to contribute to the 
regulation of the cardiovascular system through governing smooth muscle 
vasoconstriction. Vasoconstrictor signals originating in the brainstem are termed Muscle 
Sympathetic Nerve Activity, or MSNA, when directed to skeletal muscle vasculature and 
may be measured directly in humans using microneurography. The technique uses 
tungsten microelectrodes to pierce a nerve transcutaneously to record sympathetic 
axonal discharge (Hagbarth & Vallbo, 1968), and has become an important research 
topic in cardiovascular studies in normal and pathological conditions (Salmanpour, 
Brown, & Shoemaker, 2010). When recorded as a multi-unit signal, raw, filtered and 
integrated neurograms are each generated. Historically, the focus has been on 
interpreting the integrated signal, likely due to technical constraints and ease of 
interpretation, though field advancements now allow for single-unit analysis as well as 
action potential (AP) analysis of a multi-unit signal.  
The integrated signal is created from the filtered signal using a leaky integrator 
creating the bursty pattern characteristic of MSNA, and eliminating any compositional 
information about the APs from the filtered neurogram. Integrated parameters, namely 
burst frequency (bursts/min), incidence (bursts/100 heart beats) and amplitude, are 
burst characteristics which represent the response of a grouped population of axons 
firing together and provide useful quantitative information on the average strength of 
activity in the recording field (B G Wallin & Charkoudian, 2007). Though relatively new, 
AP analysis of a multi-unit recording studies recruitment strategies and firing patterns 
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through the population of axons within the recording field (Salmanpour et al., 2010). As 
APs are now able to be examined, variables congruous to burst variables now exist (eg. 
spike frequency, incidence and amplitude), as well as others like spikes/burst and AP 
clusters, which represent an amplitude based-classification of like-APs. 
With so many variables now available for analysis, it is evident that MSNA is a 
multifactorial concept. A major concern of researchers in this field is deciding which of 
all the variables collected should be used for inter-individual and group comparisons 
across age, disease, and various states of sympathoexcitation or inhibition. As such, this 
study addressed the question of which MSNA variable, or group of variables, measured 
at baseline, best describe(s) group differences. The study tested the hypothesis that 
newly available action potential information would better discriminate between groups 
than traditional integrated variables.   A MANOVA approach, which considers all 
measured variables concurrently, was used to determine which MSNA variables account 
for the most variability in a group comparison. These proscribed variables were then 
used to better understand baseline MSNA differences between groups. We tested the 
hypothesis using two group-based comparisons.  First based on age (young vs old, n≈20 
per group), and second based on cardiovascular disease (CVD) state (young healthy, old 
healthy, metabolic syndrome, coronary artery disease, and class-I and -II chronic heart 
failure, n≈7 per group).  
Subsequent Chapters will detail the literary background of MSNA and the 
sympathetic nervous system (Chapter 1) as well as the statistical approach to MANOVA 
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(Chapter 2). Chapter 3 will discuss aspects of the physiological and statistical 
methodology of the study as well as the study results. Lastly, Chapter 4 will focus on a 
discussion of the findings, concluding remarks and recommendations for MSNA data 
analysis and reporting for future studies. 
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Chapter 1 
THE SYMPATHETIC NERVOUS SYSETM & MUSCLE 
SYMPATHETIC NERVE ACTIVITY 
“Large and small arteries, arterioles and most veins are innervated by sympathetic 
noradrenergic neurons, the activation of which generates vasoconstriction” (Jänig, 2006, 
p. 107). Additionally, as skeletal muscle circulation makes up a large proportion of 
cardiac output, both at rest and during physical activity, the neural control of this 
circulation is fundamental to systemic hemodynamics (B G Wallin & Charkoudian, 2007). 
Large variances seen in health and disease, as well as between individuals, suggests that 
the sympathetic nervous system seems to play an integral part in assuring the 
cardiovascular system is maintained within an appropriate range, the dysregulation of 
which severely impacts disease and health outcomes.  
As a whole, sympathetic outflow to muscular-bound vascular beds, termed muscle 
sympathetic nerve activity (MSNA), can be measured directly using a technique called 
microneurography. This signal is influenced by several aspects including health-disease 
state, resting or manoeuver-based activity, age, sex and the recording technique used. 
This chapter is aimed at investigating the origin, composition, and modulators of the 
MSNA signal, as well as techniques for, and outcomes of, its analysis. The over-arching 
question to be addressed by this dissertation is “how should MSNA be measured, and 
subsequently interpreted?” especially given the numerous quantifiable variables 
available for analysis. 
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The ANS 
The autonomic nervous system (ANS) is used to describe the innervation of all 
structures which do not include striated muscle fibres (Jänig, 2006, p. 13). Of its many 
functions, one is cardiovascular regulation throughout the body. Primarily, the ANS is 
divided into the sympathetic nervous system (SNS), responsible for creating an 
excitatory response towards a stimulus, the parasympathetic nervous system (PNS), 
responsible for an inhibitory response and the enteric nervous system which is intrinsic 
to the gastrointestinal tract (Jänig, 2006, p. 15). Typically, these systems act in an 
opposing, yet complimentary concert to dynamically regulate the cardiovascular system. 
All regulatory signals originate in the brain and brainstem, and extend via neurons into 
the periphery to target effector organs including the heart, vasculature, and viscera. The 
sympathetic and parasympathetic systems are anatomically separate with the 
sympathetic system originating from the thoracic and upper lumbar spinal segments, 
and the parasympathetic system originating from the brainstem and sacral spinal cord 
(Jänig, 2006, p. 33).  
Neuroanatomy 
All sympathetic neural signals which eventually reach and pass through the 
periphery, originate in the brainstem, primarily the intermediolateral cell column (IML) 
(B G Wallin & Charkoudian, 2007). Many cortical structures, which are interrelated 
through both afferent and efferent pathways, have been studied with attention to the 
ANS and govern the MSNA discharge sent into peripheral nerves.  Figure 1 depicts 
traditionally recognized neural pathways between several neural centres. Though many 
3 
 
 
 
pathways exist, as deduced by c-fos mapping (Dampney, Polson, Potts, Hirooka, & 
Horiuchi, 2003) and antero- or retrograde viral tract-tracing (Loewy & McKellar, 1980), 
some of their specific functions are unknown (indicated by purple lines in the Figure 1). 
Pharmaceutical receptor blockage and agonism have been used in experimental trials to 
uncover pathways associated with specific structures as well as the receptor types 
involved through examining pre- and post-drug responses. Of particular interest are the 
relationships between the Nucleus Tractus Solitarius (NTS), (Caudal Ventrolateral 
Medulla (CVLM), Rostral Ventrolateral Medulla (RVLM), and the IML in the spinal cord, 
which represent some of the final pathways traveled in the brain before sympathetic 
nerve activity (SNA) is sent to the periphery. This pathway involves the disinhibition of 
the RVLM on the IML. This occurs through inhibition of the GABAergic (gamma-
amniobutyric acid) neurones from the CVLM, through reduced CVLM stimulation, in 
order to increase SNA (see Figure 1). This series of events occurs for example, in 
instances of low pressure when the baroreceptors are unloaded (Dampney et al., 2003) 
(see Figure 14). 
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Figure 1: Traditional Neural Pathways. Information on pathway location, direction and action:  
(derived from: Cechetto & Shoemaker, 2009; Dampney et al., 2003; Loewy & McKellar, 1980; Wong, Massé, Kimmerly, Menon, & 
Shoemaker, 2007) 
Peripheral Neurons 
SNA travels from the brainstem into the periphery to arrive at the target effector 
organ via two neural systems. Cell bodies of the first type of neuron (pre-ganglionic) 
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originate in the brain and their axons extend to synapse at the sympathetic chain (B G 
Wallin & Charkoudian, 2007). The second type of neuron (post-ganglionic), which carries 
the signal the rest of the way to the effector organ, originates here (Figure 2). 
 
Figure 2: Sympathetic Neural Transmission from Brain through Ganglia to Effector Organ 
The Sympathetic Chain 
The synapse in the sympathetic chain, or ganglion, is cholinergic and depends on the 
transmission of Acetylcholine (ACh) (Jänig, 2006, p. 15). ACh is released by the pre-
ganglionic neuron and travels to the post-ganglionic neuron in a process described by 
the following seven steps: 1) saltatory conduction occurs in the myelinated pre-
ganglionic fibre, 2) conduction proceeds to the non-myelinated pre-ganglionic terminals, 
3) ACh is released, 4) ACh crosses the synaptic gap, occupies receptors on the post-
junctional membrane and is eliminated via simple diffusion or specific hydrolysis by 
AChE (acetylcholinesterase), 5) a local response of the post-ganglionic cell to ACh occurs 
resulting in local depolarization of the membrane, 6) the propagated AP is initiated and 
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7) conduction of the signal in the non-myelinated post-ganglionic axon occurs (Perry, 
1957). The local response (step 5) is a graded response and is thus open to modulation 
whereas the propagated response (step 6) is an all-or-nothing reaction and in 
consequence can only be blocked, not modified (Perry, 1957). Transmission in the 
sympathetic chain does not occur simply between two nerves in a 1:1 ratio, but is the 
result of several pre-ganglionic nerves synapsing on fewer post-ganglionic nerves in a 
ratio that may be as high as 200:1 (B G Wallin & Charkoudian, 2007).  Summation, both 
spatially and temporally, impact the transmission of the signal from the first to second 
nerve (Perry, 1957).  
The Neural Cleft - Vasculature 
Post-ganglionic muscle sympathetic axons exist in groupings of 10-20 like-suited 
axons intermingled with other nerve types. These axons exist within a muscle fascicle 
within a nerve, and terminate in a nicotinic synapse with their target blood vessel. All 
three sympathetic neurotransmitters (NTs): adenosine triphosphate (ATP), 
norepinephrine (NE) and neuropeptide Y (NPY), function at this synapse and contribute 
to sympathetically-mediated vasoconstriction of small arteries (Bradley, Law, Bell, & 
Johnson, 2003). Bulges on the terminal end of the nerve, termed varicosities, are the 
storage location for NTs and may number as many as 20 000 per nerve axon. 
Sympathetic axons criss-cross over each vessel and directly impact adjacent or 
“innervated” VSMCs (dark grey in Figure 3). The signal is then propagated through all 
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cell layers via diffusion between the 1st and 2nd cell layers (blue arrows in Figure 3) and 
gap junctions between subsequent layers (purple hash marks in Figure 3). Both ATP and 
NE are manufactured by, stored in, and released from the vesicles within the varicosity 
at a ratio of at least 1:4 (Burnstock & Sneddon, 1985), while NPY is manufactured in the 
cell body and translocates within a vesicle to the varicosity.  
 
Figure 3: Signal Transduction in VSMCs. Blue arrows represent diffusion between 1st and 2nd cell 
layers, while purple hash marks represent gap junction transmission between subsequent layers 
NTs may be released at varying degrees from a varicosity as a product of the 
neuronal stimulation level by action potentials (APs) (Bradley et al., 2003; Jackson, 
Noble, & Shoemaker, 2004; Kluess, Buckwalter, Hamann, DeLorey, & Clifford, 2006). 
One hypothesis suggests that stimulation occurs on a continuum with an ordered 
release of ATP, NE and NPY from least to greatest stimulation levels. Figure 5 depicts the 
stimulation and vascular action of each NT with their actions ultimately causing calcium 
(Ca2+) release to facilitate vasoconstriction through the sliding filament model. The 
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vascular response to mixed NT release is bimodal with a fast, small, transient peak 
(caused by ATP) followed by a more robust constriction peaking 20-30s later (Burnstock 
& Sneddon, 1985). All NTs are affected by various neuromodulators at both pre- and 
post-junctional locations and self-regulate their release via inhibition through pre-
junctional receptors (Burnstock & Sneddon, 1985). The response to each NT is also 
tissue dependent, relying on both varying receptor concentrations and effectiveness. 
This is particularly important in determining flow patterns through the vascular tree 
(Figure 4) as different receptors have different efficacies at different locations. In 
arterioles  Y1 > α1 receptors, and in conduit and small arteries (feed arteries), α1 > Y1  
which gives the option for differential control of blood flow (Sundler, Bottcher, Ekblad, 
& Hakansone, 1993 as referenced by Jackson et al. 2004). 
Neurotransmitters: 
Adenosine Triphosphate - ATP: 
ATP allows for the fastest vascular response and is hypothesized to be released into 
the cleft at the lowest levels of neural stimulation. It acts on the postjunctional receptor 
P2x, a Ca
2+ channel allowing for the flux of calcium down its concentration gradient and 
into the cell (Figure 5a). As a result, a very short acting (~300ms) ionotropic force, called 
an excitatory postjunctional potential (ejp), is generated resulting in a local Ca2+ increase 
to cause weak tension on the cell (Wier, Zang, Lamont, & Raina, 2009). ATP also 
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activates the pre-junctional P1 receptor inhibiting further vesicular NT release (Wier et 
al., 2009). 
 
Figure 4: Vascular Tree 
Norepinephrine - NE: 
 NE is released from the varicosity under mild stress conditions, and is thought to be 
the primary NT responsible for daily maintenance of vasoconstriction. It acts on the α1 
receptor post-junctionally (Burnstock & Sneddon, 1985) to activate the GPCR, Gq, which 
activates Phospholipase C  (PLC) allowing the conversion of Phosphatidylinositol 4,5-
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bisphosphate (PIP2) to Inositol triphosphate (IP3). The subsequent actions of IP3 on 
ryanodine receptors (RYR) on the sarcoplasmic reticulum (SR) facilitate massive Ca2+ 
release and major vasoconstriction (Figure 5b). This response is much slower in 
comparison to ATP, requiring approximately 20-30s to take effect since a large pathway 
must be activated in order to release Ca2+. NE is primarily responsible for the second 
phase of the bimodal vascular response. Besides α1 activation, NE may activate pre-
junctional α2 to inhibit further NT vesicular release (Wier et al., 2009), be taken up by 
the NE transmitter (NET) to be degraded by monoamine oxidase (MAO), or diffuse into 
the venous system.  
Neuropeptide Y - NPY: 
NPY is a 36 amino acid polypeptide chain thought to be reserved for high-stress 
situations. Though NPY causes mild vasoconstriction on its own, its true ability is in 
facilitating the most robust vasoconstriction response in the vasculature when used in 
concert with other NTs, especially NE and at small arterioles (Jackson et al., 2004). This 
relationship has been described as additive (Jackson et al., 2004) by some researchers 
and synergistic by others. NPY1-36  acts post-junctionally on the Y1 receptor (Evanson, 
Stone, Hammond, & Kluess, 2011) via the g-protein coupled receptor (GPCR), Go, to 
cause PLC activation, as in the NE pathway, and also on the GPCR, Gi, to cause inhibition 
of adenylate cyclase (AC) to in turn prevent the production of cAMP which causes 
vasodilation (Figure 5c). The activation of Gi is thought to be a major pathway for NPY to 
influence the vasculature. NPY is also present in blood elements (platelets) and is stored 
11 
 
 
 
and released from the adrenal medulla (Evanson et al., 2011). NPY1-36 action may be 
modulated via truncation to NPY3-36, by Dipeptidyl Peptidase IV (DPPIV) (Evanson et al., 
2011). NPY3-36 may act upon the pre-junctional γ2 receptor to inhibit further NPY release 
from the varicosity, or act upon γ2 or γ5 receptors outside of the vasculature.  
Cotransmission 
Despite the hypothesized order of NT release, “cotransmission,” or the concept of 
ATP, NE and NPY being released at the same time, is well supported by Burnstock and 
colleagues. It raises the question, however, of how the bimodal response seen in VSMCs 
occurs, given that if this hypothesis is true, all NTs are released, even at low levels of 
stimulation. A potential argument is that NE and NPY are well controlled by mechanisms 
other than post-junctional binding such that a great concentration is needed to elicit an 
effect (eg. threshold to activity). 
  
12 
 
 
 
 
Figure 5: NT stimulation and Ca
2+
 release
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Measuring MSNA 
In this dissertation, MSNA is the primary signal of interest and is assessed as an 
indicator of sympathetic nerve activity. This signal is recorded from the post-ganglionic 
nerve typically either at the elbow from the median nerve, or at the knee from the 
common peroneal nerve. Post-ganglionic sympathetic nerves are composed of 
thousands of unmyelinated fibres, whose individual contributions to the recorded signal 
are exceedingly small, though ongoing activity can be measured from whole-nerve 
recordings because large numbers of fibres fire APs at the same time to give ‘bursts’ or 
waves of summed spikes (McAllen & Malpas, 1997). 
This section will detail the history, and technique behind this procedure as well as 
methods for its analysis. In essence, MSNA looks at the APs in the post-ganglionic nerve 
which are responsible for NT release at the effector organ. 
History 
Microneurography was developed by Hagbarth and Vallbo by 1965-66 in Uppsala, 
Sweden as a way to further examine the sympathetic nervous system (Vallbo, Hagbarth, 
& Wallin, 2004).  Though their attempt was not the first at recording neural activity in 
human subjects, this technique furthered the field to performing experiments in 
humans which were previously reserved for animal preparations. Upon examining the 
recordings, the researchers discovered that small deflections in the signal were from 
unmyelinated nerves with a conduction velocity of ~1m/s and were efferent in nature 
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which represented SNS activity (Vallbo et al., 2004). Figure 6 is from the first publication 
of human microneurography and details recordings of MSNA neurograms (raw: channel 
1, integrated: channel 2), ECG (channel 3) and electrical activity from intercostal muscles 
(channel 4) (Hagbarth & Vallbo, 1968).  
 
Figure 6: Illustration from the first publication of human microneurography. Channels 1: raw neural 
recording rom deep peroneal nerve, 2: mean voltage neurogram, 3: ECG, and 4: electrical activity from 
intercostals.  
Reprinted from Hagbarth & Vallbo, 1968 with permission from John Wiley & Sons Inc © 1968. 
MSNA Recording Techniques 
The most common way of measuring sympathetic nerve activity (MSNA) is through 
multifibre recordings (multiunit activity) (Hagbarth & Vallbo, 1968), though impulses in 
single sympathetic fibres (single unit activity) can also be measured (Macefield, Wallin, 
& Vallbo, 1994).  From the multifibre recording, AP analysis may also be completed to 
determine AP firing and recruitment strategies of system which would have been 
otherwise lost in the integration process (Salmanpour et al., 2010). This section will 
detail the technical aspects of the three aforementioned MSNA methods. 
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Multi-Unit MSNA Recording 
In this technique the active electrode, a 200μm diameter X 35mm long tungsten 
microelectrode with a resistance of 3Ω, tapering to an uninsulated 1-5μm tip, is inserted 
transcutaneously into either the peroneal or ulnar nerve (Hagbarth & Vallbo, 1968). A 
reference electrode is positioned subcutaneously 2-3cm away from the active electrode 
to help filter out some background noise intrinsic to that recording area. In practice, a 
trained microneurographer uses feedback from both the participants’ sensory 
stimulation by the electrode as well as the sound from and physical representation of 
the recording from the electrode to target the optimal electrode position.  
The initial MSNA signal, ranging from 1-10μv in amplitude, is dominated by high 
levels of environmental and bioelectric background noise that produce a low signal-to-
noise ratio (SNR) (Salmanpour et al., 2010). Thus it is pre-amplified as it is recorded 
initially with a gain of 1000 and again by a gain of 1-100 (our lab uses 75) by a secondary 
variable gain amplifier (Salmanpour, Brown, & Shoemaker, 2008a) to create the 
recorded raw signal, and improve its visualization. The raw signal is then band-pass 
filtered at a bandwidth of 700-2000Hz to eliminate very low and high frequency 
wavelengths to create the filtered signal. The filtered signal is then rectified and 
integrated to create the integrated signal (Salmanpour et al., 2008a). Integration in this 
case is accomplished with a leaky integrator set at 0.1s such that the summed 
information will degrade if new information, in the form of APs, is not added. This 
integrated signal, typically used for mulit-unit analysis, allows for visualization of the 
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characteristic bursty pattern attributed to MSNA and the analysis of whole-nerve 
recording characteristics which reflect the activity of the family or pool of neurons being 
recorded from.  AP content of the signal, such as AP morphology, temporal location and 
frequency, is however lost with integration (Salmanpour et al., 2010). Figure 7  is a 
schematic representation of a microelectrode inserted into a nerve for sympathetic 
recordings detailing types of neurograms recorded and the modification steps taking 
place in between (Salmanpour et al., 2010). Adapted from Guild et al., 2010, Figure 8 
depicts an overlay of an integrated neurogram with its respective filtered neurogram to 
illustrate the smoothing effect of integration and how the filtered signal is represented 
in the integrated form. Multi-unit recordings provide useful quantitative information on 
the average strength of activity (B G Wallin & Charkoudian, 2007) of a population of 
neurons within the recording field. 
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Figure 7: Schematic Representation of the MSNA procedure with representative examples of the raw 
filtered and integrated sympathetic nerve activity.  
Reprinted from Journal of Neuroscience Methods, Salmanpour et al., 2010, Spike detection in human muscle nerve 
activity using a matched wavelet approach, pg 345 ©2010 with permission from Elsevier 
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Figure 8: Overlay of Filtered and Integrated renal SNA from Rabbits.  
Adapted from Guild et al., 2010 with permission from John Wiley and Sons Inc. © 2010 
Isolating Muscle- from Cutaneous-Nerve Bundles 
Activity in different types of sensory and motor fibres may contribute to the 
integrated mass activity recorded from human muscle nerve fascicles (Delius, Hagbarth, 
Hongell, & Wallin, 1972). Additionally, sympathetic neural recordings can occur from 
both cutaneous- and muscle-directed vascular nerves and thus it is important to 
distinguish between the two prior to the commencement of an experiment and its 
subsequent analysis. Sympathetic cutaneous and muscle activity may be separated 
through examining the pattern of impulse activity that occurs spontaneously or in 
response to various manoeuvres (Jänig, Sundlöf, & Wallin, 1983). For instance, 
cutaneous nerve bundles may usually be identified by a dull cramp-like paraesthesia and 
the presence of neural discharges when light mechanical stimuli are applied to the skin 
19 
 
 
 
area where the paraesthesia occurred (Hagbarth & Vallbo, 1968). They will also be 
pulse-asynchronous as they are not entrained to the baroreceptors, and will respond to 
startle or arousal by light or noise. Muscle nerve bundles may also produce a dull cramp-
like paraesthesia, though responsive neural discharges occur when the muscle is 
mechanically affected by local stimuli or by muscle stretch or contraction (Hagbarth & 
Vallbo, 1968).  Additionally, the signal will respond to a sympathoexciatatory manoeuver 
including Valsalva which activates the baroreflex or apnea which activates the 
chemoreflex. The signal does not change in response to startle or arousal. Historically, 
albeit risky, pharmacological agents, like trimethaphan, were used to block the ganglia 
which abolished the MSNA signal (Figure 9) (Delius et al., 1972) indicating the efferent 
nature of the signal as well as its passage through the ganglia.   
 
Figure 9: The effect of IV infusion of trimethaphan on MSNA. The arrow at 14min indicates when the 
position was changed from 20 Head-up Tilt (HUT) to horizontal.  
Reprinted from Delius et al., 1972 with permission from John Wiley & Sons Inc. © 1972. 
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With these characteristics in mind, a set of criteria was developed to allow for signal 
origin and nature determination without the use of pharmacological agents. These 
criteria include:   
1) the signal reveals spontaneous, pulse-synchronous bursts of neural activity,  
2) taps on the muscle belly and passive muscle stretch evoke afferent 
mechanosreceptive impulses,  
3) no afferent neural response is induced by skin simulation or startle, and  
4) weak electrical stimuli delivered through the recording electrode produce 
muscle twitches without concomitant skin paraesthesia (Sundlof & Wallin, 1977). 
Single-Unit Analysis 
Single unit analysis focuses on exploiting technicalities of multi-unit 
microneurography to make a single axon’s APs stand out from the rest of the signal 
based on amplitude. Since the amplitude of an AP is related to the distance of its 
originating axon from the electrode tip, large APs in axons with close electrode 
proximity will dominate the signal. In this technique, electrodes akin to those used in 
multi-unit recordings, to the exception of their resistance, are used. The increased 
resistance of single-unit electrodes (10Ω as opposed to 3Ω) decreases the overall size of 
the recording area around the electrode tip allowing for a smaller recording field and 
less background signal to separate from the targeted APs. The idea is to cosy up to a 
large axon and based on the concept that axons exude APs with a signature size and 
shape, extract large similar looking APs from the MSNA signal for further analysis (see 
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Figure 10). This procedure is done using an algorithm-based unit retrieval system on the 
basis of morphology where APs are included as part of that axonal set if they match 
(starred spikes in Figure 10) (Macefield & Wallin, 1999). As an outcome, the greater 
gestalt of neuronal firing is ignored, while a single axon’s behaviour is studied in depth. 
 
Figure 10: Single Unit Recording from a CHF patient showing signals recorded (raw MSNA, integrated 
MSNA, ECG, BP and respiration) as well as superimposed spikes with uniform morphology indicating 
that action potentials are from the same axon. 
Reprinted from Macefield, V. G., et al. (1999). Firing Properties of Single Muscle Vasoconstrictor Neurons in the 
Sympathoexcitation Associated With Congestive Heart Failure. Circulation, 100, 1708–1713. © with permission from 
Wolters Kluwer. 
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AP Analysis 
Field advancements allowing for AP detection in the filtered multi-unit signal allows 
for research to be directed towards exploring the fundamental recruitment and pattern 
of axonal discharge which ultimately creates the integrated signal. This secondary step 
to the multi-unit recording restores the capability to analyse individual AP morphology, 
and frequency which is obscured by the integration process (Salmanpour et al., 2010).  
Since the detection of APs in the filtered signal is difficult due to  a considerable 
amount of noise, a mother wavelet adapted to an average physiological AP waveform is 
applied to the filtered signal by way of a continuous wavelet transform (CWT) to provide 
a wavelet coefficient between the signal of interest (AP) and the mother wavelet 
(Salmanpour et al., 2010). This coefficient is largest in the presence of APs and is 
negligible when applied to noise (C & D in Figure 12) (Salmanpour et al., 2010) which 
allows separation based on thresholding analysis (Johnstone & Silverman, 1997). Prior to 
AP detection, the temporal location of each burst of APs in the file is denoted by 
manually inserting a marker on the burst peaks of the integrated multi-unit signal within 
the original labchart file which has been shifted, along with the filtered and raw MSNA 
channels, backwards by the burst latency (measured beforehand) value. Burst peaks 
should align with ECG r-waves (encircled in Figure 11) and diastolic blood pressures 
when shifted by the latency. The LabChart labelling procedure is detailed in Figure 11. 
Each “burst” marker denotes the centre of a 800ms window which will be extracted 
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from the corresponding filtered signal and examined by the matlab-based program for 
AP detection.  
 
Figure 11: Burst Labelling in raw LabChart Files denotes data segments for subsequent AP analysis 
The identified APs are then marked with a second predefined window of 3.2ms (the 
maximum time for AP conduction) and are extracted from the filtered signal thereby 
preserving the amplitude and morphology of all extracted APs (Steinback, Salmanpour, 
Breskovic, Dujic, & Shoemaker, 2010). Figure 12  (Salmanpour et al., 2010) displays a 
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breakdown of the AP detection procedure with each letter representing a different 
portion of the process: (A) the filtered signal from a single MSNA burst (0.8s), originally 
marked in the lab chart file (as in Figure 11), (B) an enlarged portion of the signal in A 
with labelled APs, (C) wavelet coefficients using a matched wavelet, horizontal lines 
show wavelet thresholds with sharp and tall peaks occurring around labelled APs, (D) 
wavelet coefficients related to the labelled APs after wavelet thresholding, local maxima 
shows the location of APs (filled circles), (E) APs extracted from B by using the estimated 
location centered at a 3.2ms window, and (F) all APs extracted from A. 
 
Figure 12: Action Potential Detection Procedure in a Single MSNA burst  
Reprinted from Journal of Neuroscience Methods Salmanpour et al., 2010, Spike detection in human muscle nerve 
activity using a matched wavelet approach, pg 350 ©2010 with permission from Elsevier 
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Extracted APs are subsequently sorted based on their amplitude into Scott’s rule 
derived size-based bins to form clusters of like-APs for further analysis. Overall, this type 
of analysis focuses on understanding recruitment strategies of axons through regarding 
all APs from a population of axons within the recording field. 
What Makes a High-Quality Signal? 
Traditionally, researchers studying MSNA look for a signal that fits the 
aforementioned criteria used to confirm the signal as being muscle-sympathetic (see 
Isolating Muscle- from Cutaneous-Nerve Bundles), as well as listen for its characteristic 
sound throughout the recording. In inspecting the filtered and integrated neurograms 
off-line, a good signal should have a high SNR such that bursts can be seen in the filtered 
SNA signal and in the integrated SNA neurograms (Guild et al., 2010). Though depicting 
renal SNA in rabbits, Figure 13 illustrates the difference between good and poor quality 
SNA (sympathetic nerve activity) signals as evidenced in the integrated and filtered 
signals (Guild et al., 2010). Lastly, it is important to consider the stability or quality of a 
recording over time (Guild et al., 2010) as changes in either quality or stability of the site 
may indicate either a problem with the recording site or, a change in activity. This is 
particularly important with regards to within-individual comparisons across a recording 
period. 
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Figure 13: Good and Poor Renal SNA signals in Rabbits 
Reprinted from Guild et al., 2010 with permission from John Wiley and Sons Inc. © 2010 
Risks 
When performed properly, MSNA has a very low probability of producing sustained 
nerve damage. Eckberg et al conducted a review of 645 microneurography studies 
showing that only 9% of subjects experienced numbness, paresthesia, pain, or 
tenderness at or distal to the site of electrode insertion following the study, the effects 
of which almost always disappeared within 14 days (Eckberg, Wallin, Fagius, Lundberg, 
& Torebjörk, 1989). The median onset time for symptoms was 2 to 3 days and they 
usually lasted 3 to 7 days, with resolution within 14 days in 95% of cases (Eckberg et al., 
1989).  Based on these findings, Eckberg et al recommend that manipulation for the 
microelectrode should be limited to one hour and that the same nerve should not be 
restudied within one month (Eckberg et al., 1989). Though minor aftereffects have been 
documented, it is important to recognise that microneurography is an invasive method 
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that involves the exploration of delicate structure that may suffer from improper 
procedures (Vallbo et al., 2004).  
The Recorded Signal – MSNA Characteristics 
Due a combination of baroreceptor disinhibition, and the leaky integrator used 
during recording, sympathetic neural activity consists of bursts of impulses occurring 
pulse synchronously in short, rather irregular sequences, separated by periods of 
relative silence (Hagbarth & Vallbo, 1968). Additionally, the strength of the neural 
activity, specifically burst amplitude, is dependent not only on the number of impulses 
but also on their amplitude and the proximity of axons to the active electrode. Thus, 
frequency changes in the fibres closest to the recording surface will dominate over 
similar changes elsewhere (Delius et al., 1972).  
Specifically, MSNA characteristics are used for two purposes: to help identify the 
recording as being muscle sympathetic (as described in Isolating Muscle- from 
Cutaneous-Nerve Bundles) or to interpret and analyse the signal for comparison. Of all 
measureable MSNA qualities, its cardiac periodicity or entrainment, producing the 
bursting pattern evident in the integrated neurogram, is one of the most pronounced. 
Adrian et al. suggested that cardiac periodicity was due to a relatively continuous level 
of ongoing drive being periodically interrupted by afferent signals reaching the 
brainstem from baroreceptors (Adrian, Bronk, & Phillips, 1932). Baroreceptors are 
viscoelastic, mechanosensitive, elements which respond to stretch in the vessel wall in 
28 
 
 
 
which they are positioned. Thus, MSNA activity increases in accordance with decreases 
in blood pressure (BP) and is inhibited by the baroreflex when pressures are high (Delius 
et al., 1972; Jänig et al., 1983). The integrated pattern is result of several pre-ganglionc 
fibres  (Ninomiya, Malpas, Matsukawa, Shindo, & Akiyama, 1993) firing synchronously 
(McAllen & Malpas, 1997). Bursts are a population phenomenon, not usually evident in 
the firing of an individual neuron and are coordinated between different pre-ganglionic 
neurons, as seen as a good burst-for-burst correspondence between different recording 
sites (McAllen & Malpas, 1997). There are large, reproducible inter-individual 
differences in the level of MSNA at rest, like burst frequency (Kimmerly, O’Leary, & 
Shoemaker, 2004), and there is no significant correlation between a subjects level of 
MSA and their BP (blood pressure) (Delius et al., 1972; Sundlof & Wallin, 1977, 1978). In 
addition to baroreflex modulation, MSNA is impacted by the chemoreflex, located either 
centrally or peripherally (Kara, Narkiewicz, & Somers, 2003). Lastly, activity in 
vasoconstrictor neurons frequently displays grouping of impulses with the rate of 
respiration which is dependent on the central coupling between respiratory and 
cardiovascular neurons, usually related to the respiratory fluctuations of BP (Delius et 
al., 1972; Jänig et al., 1983).  
The Baroreflex 
The baroreflex allows for fluctuations in heart rate or vascular tension to maintain a 
tight range of BPs around a given mean arterial pressure (MAP). The baroreflex, 
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perceived by baroreceptors (BRs), activates in hypertension (HTN) and is removed in 
hypotension. BRs are viscoelastic elements found in three locations: the carotid sinus, 
the aortic arch and the heart/pulmonary vasculature. Influence on the heart and 
vasculature as targets of the reflex is mediated through a central neural pathway 
involving baroreflex excitation of the NTS via cranial nerves (CN) IX and X, which excites 
the CVLM leading to RVLM inhibition and decreased SNA outflow (see Figure 14). 
 
Figure 14: Baroreceptor Activation leading to MSNA recording 
The Chemoreflex 
Chemoreflexes are important modulators of SNA and are of particular interest when 
studying health and disease states. Chemoreceptors exist peripherally and centrally 
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(Table 1) and lead to hyperventilation and sympathetic activation when stimulated, with 
a greater response resulting from peripheral receptors. Operating as a negative 
feedback loop, pulmonary stretch afferents activated in hyperventilation, and arterial 
baroreceptors activated with increased BP inhibit the chemoreflex (Figure 15).  
Table 1: Chemoreflex Locations and Characteristics 
Type Location Responds to Exacerbated by 
Peripheral Carotid Bodies Hypoxia HTN, obstructive sleep apnea, Heart Failure 
Central Brainstem Hypercapnia Heart Failure 
 
 
Figure 15: Implications of Peripheral and Central Chemoreflex activation  
MSNA Modifiers 
MSNA may be modified by several short- and long-term modifiers. Short-term 
modifiers include: position (supine, seated or standing), arousal, hypoxia, hypercapnia, 
exercise, circulating hormones or the performance of sympathoexcitatory or inhibitory 
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manoeuvers which influence the baro- or chemoreflexes. For instance, movement from 
supine to seated to standing posture results in progressive increases in sympathetic 
neural activity (Burke, Sundlof, & Wallin, 1977) which are “part of normal baroreflex 
responses aimed at the maintenance of cerebral perfusion pressure during gravity-
induced decreases in venous return” (B G Wallin & Charkoudian, 2007). Additionally, 
hypercapnia (see Figure 15) is a large stimulus for sympathoexiciation via central 
chemoreceptor activation (Somers, Dyken, Clary, & Abboud, 1995). Inhibition may occur 
in cases of lung inflation, from stimulation of pulmonary vagal afferents (Seals, Suwarno, 
& Dempsey, 1990), in sudden chest compression or mild electrical shock (Delius et al., 
1972). Long-term modifiers, such as age and disease and sex will be further discussed 
below. 
Effects of Age  
Normal human aging is associated with progressive increases in resting activity of 
sympathetic nerves to skeletal muscle, the heart, and the splanchnic area (Seals & Esler, 
2000). The estimated increase in resting MSNA is about 1 burst/min per year (Fagius & 
Wallin, 1993). There is also a significant correlation between MAP (mean arterial 
pressure) and MSNA in both men and women over 40 years of age, but not less than 40, 
suggesting that the age related increase of MSNA contributes to an increase of BP 
(Narkiewicz et al., 2005). The mechanism behind this increase in MSNA with age has 
been postulated to be an age-related impairment in baroreflex sensitivity (Rowe & 
Troen, 1980; Sundlof & Wallin, 1978).  
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Effects of Sex 
Sex appears to be an important determinant of the absolute level of MSNA in both 
young and older humans which is not always reflected by venous norepinephrine (NE) 
concentrations (Ng, Callister, Johnson, & Seals, 1993). Women seem to have more 
marked increases in MSNA with aging (Matsukawa, Sugiyama, Watanabe, Kobayashi, & 
Mano, 1998) which may be related to the fact that younger women have on average, 
lower levels of resting activity than men (Shoemaker, Hogeman, Khan, Kimmerly, & 
Sinoway, 2001). There is also evidence that the baroreflex control of SNA is affected by 
reproductive hormone status during menstrual cycle (B G Wallin & Charkoudian, 2007). 
Additionally, changes in MSNA variables are not consistent between sexes which 
suggests gender specific autonomic responses to cardiovascular stress (Shoemaker et 
al., 2001). 
Effects of Disease 
In the overall population, the prevalence of various chronic diseases, including 
coronary artery disease, obesity, and physical inactivity, all increase with age and could 
influence ANS function independent of biological aging processes  (Ng et al., 1993). 
Furthermore, these diseases or impairments often coexist compounding risk factors and 
outcomes across disease classifications. Many present with hypertension and obesity 
which will be discussed below. From an SNA standpoint, MSNA is progressively greater 
in hypertensive subjects and those with obesity and chronic heart failure (CHF) in 
comparison with healthy control subjects (Yucha, 2000). Additionally, high sympathetic 
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activity to resistance vessels has been associated with the development of a number of 
vascular changes (Julius, 1991) which may promote the pathogenesis and adverse 
consequences of these diseases. 
Metabolic Syndrome (MET) 
Metabolic syndrome is characterized by a cluster of abnormalities including insulin 
resistance, visceral obesity, hyptertension, dyslipidemia, glucose intolerance and a 
systemic proinflammatory state as well as increased SNS activity (Straznicky, Eikelis, 
Lambert, & Esler, 2008). Seen in Figure 16, individuals with metabolic syndrome often 
also display increased cytokine, adipokine, nonesterified fatty acid (NEFA), and leptin 
concentrations, as well as obstructive sleep apnea (OSA), β-adrenoreceptor (β-ADR) 
polymorphisms, decreased baroreceptor sensitivity (BRS) and increased renin-
angiontensin-aldosterone system (RAAS) activation as a result of their obesity which, 
when taken together, may contribute to increased sympathoexcitation and further 
pathogenesis of the syndrome (Straznicky et al., 2008). 
Obesity 
Increases in body weight and associated adipose tissue accumulation are associated 
with increases in resting MSNA in human subjects (see Figure 16) (Scherrer et al., 1994). 
Normotensive obese individuals have been shown to have MSNA that is, on average, 
more than twice as high as normotensive lean individuals matched for age (Grassi et al., 
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1995). Sympathoinhibition of this excited state can be achieved by weight loss and 
aerobic exercise training (Straznicky et al., 2008). 
 
Figure 16: Schematic diagram of potential pathophysiologic relationships between Metabolic Syndrome 
Attributes and SNS Activity  
Reprinted from Current Hypertension Reports, Straznicky et al., 2008, figure 1, with kind permission from Springer 
Science and Business Media © 
Hypertension (HTN) 
Because the SNS is important in BP control, many believe that abnormal sympathetic 
activity contributes to the development and/or maintenance of HTN (Yucha, 2000). HTN 
also results in an exaggerated responsiveness to peripheral chemoreflex activation via 
hypoxia or hypercapnia (see Figure 15) (Somers, Mark, & Abboud, 1988). 
Coronary Artery Disease (CAD) 
Athlerosclerosis is the disease process underlying CAD (Bogaert, Dymarkowski, & 
Taylor, 2005) and impacts the arterial vessel wall over time such that plaques develop 
reducing their compliance and increasing their stiffness leading to HTN. This stiffening 
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also leads to poorer vascular mechanics in the area, and if larger plaques develop, may 
lead to a significant cardiac event, or even chronic heart failure, accounting for 52% of 
incident heart failure in the general population under 75 years (Fox et al., 2001). 
Chonic Heart Failure (CHF) 
The term CHF represents all cases which are not de novo in origin and is 
characterized by signs of pulmonary congestion, including pulmonary edema, and is 
often punctuated by acute exacerbations (Swedberg et al., 2005). Patients show 
symptoms of heart failure, typically breathlessness or fatigue, either at rest or during 
exertion, or ankle swelling and should also have objective evidence of cardiac 
dysfunction, systolic and/or diastolic, at rest, preferably confirmed echocardiography 
and may show a response to treatment directed towards heart failure (Swedberg et al., 
2005). The New York Heart Association classifies HF into four categories explained in 
Table 2 (American Heart Association, 2013). The CHF participants assessed for the 
second study in this dissertation were class I and II. 
Table 2: New York Heart Association classification of heart failure  
Adapted from: American Heart Association, 2013 
Class Functional Capacity 
I 
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, 
palpitation, dyspnea or angina pain 
II 
Slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea or angina pain 
III 
Marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity 
causes fatigue, palpitation, dyspnea or angina pain 
IV 
Inability to carry on any physical activity without discomfort. Symptoms of heart failure or the 
angina syndrome may be present even at rest. If any physical activity is undertaken, discomfort 
increases 
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CHF is associated with marked increases in resting MSNA (Leimbach et al., 1986). In fact 
all MSNA parameters increased with disease severity and are significantly reduced with 
heart transplant (Sverrisdóttir, Rundqvist, Johannsson, & Elam, 2000). From a single-
fibre recording perspective, Macefield and colleagues found the elevation in MSNA in 
CHF to be derived from axon activation in a larger proportion of cardiac intervals than in 
healthy subjects but retaining the propensity to only fire once per cardiac interval 
(Macefield, Rundqvist, Sverrisdottir, Wallin, & Elam, 1999). 
Interpreting the MSNA Signal 
Historically, from a literary reporting perspective, burst frequency (bursts/min) and 
burst incidence (bursts/100 heart beats) have been the most highly reported measures 
of MSNA discharge, though the quantification of other measures including Burst 
Amplitude, Burst Latency and Burst Area from the integrated signal, as well as AP 
measures from AP and single fibre analysis including Spike Frequency or Incidence, 
Spikes/Burst, Number of Clusters, and Clusters/Burst are available. The next section will 
detail the variables available for analysis from MSNA recordings as well as their 
respective understanding in physiology. 
Measurable Variables – Integrated Signal 
Many separate variables from the integrated signal are available for analysis. Most 
commonly, the literature reports values for burst frequency, incidence and amplitude 
though others mentioned here contribute to the overall concept of MSNA. It has been 
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hypothesised that distinct neurovascular functions are accomplished by the differential 
pattern MSNA burst frequency and amplitude, which serve different yet complimentary 
roles in reflex cardiovascular control (Kimmerly & Shoemaker, 2003), though this 
interrelated nature could extend beyond these two measures to include them all. Table 
3 displays a summary of important MSNA variables examined in this study. 
Burst Frequency 
Burst frequency is measured as the number of bursts per minute and ranges from 
one through 60 or more, with a median value in young adults around 20-30 (Fagius & 
Wallin, 1993). It represents the central generation and entrainment of APs to pulsatile 
input from arterial baroreceptors (Guild et al., 2010). This measure is often reported in 
the literature as it is attainable strictly from the integrated neurogram, is reproducible, 
and not affected by electrode position in the nerve (Kimmerly & Shoemaker, 2003). 
Burst Incidence 
Burst incidence is measured as the number of bursts occurring within 100 heart 
beats (hb). Depending on several factors including disease state, incidence may vary 
from less than 5 bursts/100hb to a maximal 100 bursts/100hb (Fagius & Wallin, 1993). It 
is somewhat of a standardization of burst frequency to heart rate for comparison 
between individuals and represents the central impact on MSNA discharge as it 
integrates baroreceptor input into the measure. 
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Burst Amplitude 
Burst amplitude reflects the number of fibres firing together, based on both the 
number of recruited neurons and multiple firings of a given neuron (Ninomiya et al., 
1993) and is controlled independently from burst probability (McAllen & Malpas, 1997) 
and frequency/incidence (Kienbaum, Karlssonn, Sverrisdottir, Elam, & Wallin, 2001; 
McAllen & Malpas, 1997). Burst amplitudes are variable, even between consecutive 
bursts under stable conditions (Sundlof & Wallin, 1978). In its absolute form, burst 
amplitude is a function of electrode proximity to active nerve fibers (Kimmerly & 
Shoemaker, 2003) as well as the number of active fibres. Though it and other amplitude 
derivatives (eg. Burst Area) are useful for comparisons across continuous and stable 
study periods for an individual subject, they cannot be used for comparisons between 
subjects (Yucha, 2000). 
Relative Burst Amplitude 
One way to avoid issues in comparing burst amplitude between subjects is to 
normalize all of the amplitudes to the largest (Sverrisdóttir, Rundqvist, & Elam, 1998) or 
average baseline burst which is set at 100%. From here, each burst may be represented 
as a percentage of the chosen baseline standard and a burst amplitude distribution may 
be created. These distributions may be used for comparison between individuals or 
groups. Sverrisdottir et al. found that relative burst amplitude distribution is shifted 
toward larger bursts before the occurrence of a significantly augmented burst 
frequency, suggesting that analysis of MSNA burst amplitude distribution may provide a 
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more sensitive indicator of altered sympathetic discharge particularly  in early stages of 
CHF (Sverrisdóttir et al., 2000). This approach has also been used to examine lower body 
negative pressure (LBNP, a baroreflex stress), and hypovolemia (Kimmerly & Shoemaker, 
2003). 
Burst Latency 
Typically, burst latencies, for recording from the peroneal nerve, range from ~0.8-
1.4s and approximate ~0.95s when recorded from the median nerve (Delius et al., 
1972). These values are measured as the length of time from the preceding R-wave to 
the peak of the burst in question which is taken as the start of inhibition (B G Wallin & 
Charkoudian, 2007). It represents the time taken for the baroreflex to remove its 
inhibition of the sympathetic signal in the brain, as well as the neural conduction time 
from brain to recording site. In unmyelinated fibres, the velocity of neural impulses is 
~1m/s. There exists a hierarchical pattern of recruitment of additional faster conducting 
neurons of larger amplitude and smaller latencies as the sympathetic bursts become 
stronger (Salmanpour et al., 2011). 
Mean Burst Area or Total MSNA 
Total MSNA can be represented by burst frequency (no. of bursts/min) multiplied by 
average burst area (B G Wallin & Charkoudian, 2007) and is measured in v/s2. It is 
representative of the overall total MSNA signal, and can only be used in an unchanged 
electrode site for within-individual comparison due to its amplitude component. 
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Inter-Burst Interval 
The interval between bursts is expected to be equal to or a multiple of the R-R 
interval (the time between sequential R waves) on the electrocardiogram (Yucha, 2000). 
It is similarly influenced by factors which affect burst latency as it is dependent upon the 
separation of subsequently firing bursts which each have a respective latency. 
Measurable Variables – Action Potential (AP) Signal 
Like, burst-based variables, several complementary AP-specific variables are 
available for interpretation. Equivalent to Burst Frequency and Incidence are measures 
of spikes (or APs)/min or /100hb. Together, with spike amplitude, these measures are 
the fundamental components of the real raw neurogram that are smoothed out to 
create the integrated signal. Furthermore, spike amplitude is used to bin detected APs 
based on their peak-to-peak size for further analysis. This binning creates clusters or 
like-sized APs which can be analysed as a group. Cluster analysis allows for the detection 
of newly activated neurons under higher stress levels (Steinback et al., 2010). In parallel 
to the burst analysis, spike latency and inter-spike-interval can also be assessed. Lastly, 
spikes/burst as well as clusters/burst may be analysed as new forms of grouping spike 
data. Taken together, these new analysis variables allow for a more in depth look at the 
composition of the MSNA signal. Though represented in bursts of the integrated signal, 
none of this information was available without direct attention to its de-noising, filtering 
and assessment (as described in AP Analysis). Looking at the integrated signal alone may 
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be misleading or restrictive as its fundamental composition cannot be examined which 
is important for understanding recruitment properties of the system. 
AP Recruitment 
One reason why AP analysis is of particular interest is that recruitment patterns of 
APs, which are the fundamental signal transmission unit, are able to be observed with 
this new technique. In 1994, Wallin et al. observed that larger bursts typically have a 
shorter conduction latency which suggested that 1) synaptic delays within sympathetic 
reflex arcs could be modified so that neurones are recruited earlier in the cardiac cycle, 
or that 2) that a latent population of neurones may exist that have a faster conduction 
velocity such that their signal contributes to the integrated output earlier (B G Wallin, 
Burke, & Gandevia, 1994). Following this, through looking at AP signals in healthy males 
under high chemoreflex stress, Steinback et al. observed a latent population of large 
sympathetic neurons which generated large APs with faster conduction velocities which 
were silent at rest (Steinback et al., 2010).  
Though previously the focus of AP detection was aimed at examining recruitment 
patterns and characteristics in reflex-based scenarios, this study used this analysis as a 
way to uncover baseline MSNA AP characteristics to determine this AP-based 
information could be used to distinguish between groups of varying age and CVD health 
status. 
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Measurable Variables – Single Unit Recordings 
Single unit recordings provide information about impulse frequency and discharge 
characteristics in an individual fiber, and how such characteristics vary between fibers (B 
G Wallin & Charkoudian, 2007). Since this analysis looks at the spikes generated by a 
single axon, it may be useful to relate firing to the number of cardiac intervals by 
calculating a probability of firing for a unit (% cardiac intervals associated with spikes) 
and the probability of multiple spikes in a cardiac interval (% cardiac intervals with >1 
spike). At the single fiber level, resting firing frequency is ~0.4 Hz, probability of firing 
~30%, and probability of multiple spikes ~30% (Macefield, Elam, & Wallin, 2002). 
MSNA Conservation over Time 
MSNA is known to vary considerably between healthy subjects, whereas in a given 
individual, the level of MSNA is stable over weeks and months. In a study assessing 
MSNA levels 12 years apart in the same subjects, Fagius et al. found that subjects 
maintained their level of MSNA displayed previously, although with a slight but 
significant tendency towards a higher outflow with increasing age (Fagius & Wallin, 
1993). Kimmerly et al. also found that burst frequency within an individual is highly 
reproducible over time (Kimmerly et al., 2004).  
Subject-Specific MSNA Characteristics 
It has been suggested that for each individual there is a characteristic BP threshold 
below which the bursts occur and above which they disappear (Sundlof & Wallin, 1978). 
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Additionally, there seems to be a genetic determination of inter-individual differences in 
MSNA as supported by the observation of similar MSNA strength in monozygotic twins 
(B. G. Wallin, Kunimoto, & Sellgren, 1993). 
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Table 3: Summary of Important MSNA Variables 
Recording Technique Measured Variable Units Physiologic Relevance 
Multi-unit – 
integrated 
 
Burst Frequency min
-1 
 Reproducible 
 Compare populations 
 Reflects central generation and 
entrainment of APs 
Burst Incidence hb
-1  includes interpretation of baroreflex 
(Bx) with burst frequency aspects 
Burst Amplitude v 
 reflects # of fibres firing 
 subject to electrode proximity 
 useful for comparing across an 
individual signal, but not populations 
 can standardize (relative burst amp) 
Burst Latency s 
 reflects time for signal generation and 
conduction 
 hierarchial pattern of recruitment of 
faster conducting neurons with 
smaller latencies 
Mean Burst Area v/s 
 Total AP activity for that burst 
 useful for comparing across an 
individual signal, but not populations 
Mean Burst Area/min v/s
2  standardizes mean burst area 
measure to time 
Multi-unit – filtered 
(AP) 
 
Spikes/min min
-1 
 reflects central generation of APs 
 fundamental component of integrated 
signal 
Spikes/100hb hb
-1
 
 includes interpretation of Bx with 
spikes/min information 
Spikes/burst burst
-1 
 fundamental component of integrated 
signal 
 true representation of burst 
composition 
Spike Amplitude v 
 combination of size of axon firing as 
well as proximity to electrode tip 
 useful for comparing across an 
individual signal, but not populations 
 can be binned on size (clusters) 
Cluster n.u. 
 groups like-APs based on size 
 allows for recognition of new, large AP 
recruitment under high stress 
Clusters/burst burst
-1
 
 allows for examination of burst 
characteristics along with 
compositional spike sizes 
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Other Measures of Sympathetic Activity 
Prior to the advent of microneuography, regional blood flow and estimates of 
vascular resistance (Delius et al., 1972) as well as BP, heart rate or heart rate variability, 
skin temperature, skin conductance and blood levels of epinephrine and norepinephrine 
have been accepted as representative of SNS activity (Yucha, 2000).  
NE Spillover to Plasma 
As the rate of NE spillover into venous blood of an organ is usually proportional to its 
rate of sympathetic firing (Esler et al., 1988), NE spillover to plasma may be measured in 
venous blood draws throughout an experimental protocol as an indicator of sympathetic 
activity. NE in plasma is derived largely from transmitter released by sympathetic 
nerves, with a small contribution from the adrenal medulla and little to no input from 
the central nervous system (Esler et al., 1988). In considering this method of 
sympathetic activity analysis, the location and pathways of NE release, clearance and 
existence must be considered. Possible factors influencing the rate of NE spillover from 
organs to plasma include: MSNA firing rate, nerve density, organ mass, synaptic cleft 
width, capacity for NE uptake, capillary permeability to NE, blood flow and disease state 
(Esler et al., 1988). In addition,  the underlying assumption when sampling from venous 
circulation is that NE is evenly mixed throughout, is a misconception as regional 
differences in concentration exist dependent upon local process of NE release and 
removal (Esler et al., 1988). Figure 17 details locations and fates of systemic NE 
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including: 1) tissue concentration of NE, rate of NE release from sympathetic 
varicosities, 3) intrasynaptic concentration of NE, 4) rate of spillover of released NE to 
plasma, 6) plasma concentration of NE and 7) urinary excretion of NE and its 
metabolites (Esler et al., 1988). In the plasma, NE represents transmitter overflow rather 
than circulating hormone, and under most circumstances is devoid of metabolic and 
cardiovascular effects (Esler et al., 1988). Additionally, because of the response time 
required to influence NE concentration and its half-life, it is not possible to correlate 
these measures with minute-by-minute activity (B G Wallin & Charkoudian, 2007; Yucha, 
2000). Though there exists a significant positive correlation between MSNA (Burst 
Frequency and Incidence, (Ng et al., 1993)) in plasma NE concentration (B G Wallin et al., 
1981), plasma norepinephrine concentrations do not always reflect age- and gender-
related differences in sympathetic nervous system activity to skeletal muscle, even in 
normotensive healthy humans (Ng et al., 1993). Thus it is important to recognize the 
nature of these collected values and use caution to ascertain with what degree of 
validity they may represent sympathetic activity.  
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Figure 17: NE Fates within the Body and Composition of its Measurement  
Reprinted from Hypertension, Esler et al., 1988, Assessment of human sympathetic nervous system activity from 
measurements of norepinephrine turnover. Vol 11, iss 1, pg 4 with permission from Wolters Kluwer Health, © 
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How Should MSNA be Measured? 
The debate over how MSNA should be measured and what the traditionally 
recorded signal means is not new. A question of a 1977 paper by Sundlof and Wallin was 
concerned with “whether the patterning and strength of the muscle nerve sympathetic 
activity, as recorded from a given site in a limb muscle nerve and visualized in a ‘mean 
voltage’ display, is representative of sympathetic outflow to extremity muscles in 
general and can provide a quantitative measure of muscle nerve ‘sympathetic’ tone in a 
given subject” (Sundlof & Wallin, 1977). Through measuring baseline MSNA at several 
sites concurrently in healthy young to middle aged (21-54yrs) subjects, they concluded 
that both burst incidence and amplitude are relatively constant in the same individual 
over time and that the multi-unit recording technique can be used for comparing the 
level of MSNA between different subjects (Sundlof & Wallin, 1977). Despite this 
however, other studies have found that different MSNA parameters like frequency and 
incidence may change differently in comparison to mean burst amplitude as a result of 
age or that certain measures like relative burst amplitude distribution may be a more 
sensitive measure of an altered SNA state in CHF (Sverrisdóttir et al., 2000). Additionally, 
the AP compositional make-up of the integrated signal, as assessed in single-unit 
recordings varies in health and disease (Elam, McKenzie, & Macefield, 2002). With this 
being the case, and several techniques available to assess sympathetic activity in 
humans, each with their respective advantages and disadvantages (Grassi & Esler, 
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1999), the answer to the question of which variable should be measured and reported 
as indicative of overall MSNA levels becomes ambiguous.  
 For much of MSNA’s history, burst frequency, incidence and amplitude have 
dominated as the most reported values to express MSNA (Guild et al., 2010), potentially 
because of ease of analysis or availability, but the concern is that some of the overall 
MSNA picture has been left out as a result. MSNA is a multi-faceted phenomenon with 
many variables available for interpretation which together represent the overall 
concept. As such, with the aforementioned physiology in mind, and the understanding 
that all physiological contributions to sympathetic outflow as a whole are widely 
represented to varying degrees amongst interpretable and yet undiscovered 
parameters, the author suggests that MSNA be analyzed using a multivariate approach 
to i) ascertain group differences based on a canonical combination of all MSNA variables 
and ii) determine the variables which account for the most variability associated with a 
group difference such that the reporting of MSNA variables becomes specific and 
affirmed to where group differences are expected to lie. 
Chapter 2 will focus on describing the background and uses of multivariate statistics, 
specifically aimed at understanding its application in various contexts. Chapter 3 will 
examine two group comparisons of baseline MSNA data. In the first comparison, young 
and old subjects will be compared using a multivariate approach to look at differences 
at overall MSNA levels as assessed by a canonically derived MSNA variable. Additionally, 
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this group will be assessed using a Step-down/MANCOVA approach to determine which 
variables contribute to the most variability in the group difference. The same analysis 
procedure will be completed for the second group comparison looking at baseline MSNA 
differences across a spectrum of CVD including: young healthy, old healthy, old 
metabolic syndrome, old coronary artery disease and old chronic heart failure 
individuals. 
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Chapter 2: 
MULTIVARIATE STATISTICAL APPROACH: 
When considering group comparisons in an approximately normally distributed set 
of data, an experimenter must be concerned with the questions being asked, and the 
nature of desired comparisons. In exercise physiology, a 2 or 2+ group comparison 
across a single dependent variable is quite common and is typically interpreted using a 
student’s t-test or Analysis of Variance (ANOVA) respectively. A problem arises however 
when several dependent variables are interrelated and together describe an overall 
concept. Choosing just one variable of this set for analysis could miss part of the overall 
picture that a researcher wishes to examine. For example, in considering the description 
of a person’s gait, several quantifiable parameters, including step length, cadence, 
velocity and sway, contribute to understanding the overall concept of gait may be 
examined. Understandably, these parameters are inherently correlated with each other, 
though at various and unknown levels, and function as a cohesive unit to describe a gait 
pattern. Thus, it seems logical to interpret them together as a unit, rather than as 
separate entities as would be done in a series of ANOVAs. Instead, the use of 
Multivariate Analysis of Variance (MANOVA) can be quite productive in navigating this 
challenge.  In general, multivariate statistics may be applied when: 
(1) The researcher is interested in the effects of treatments on several criterion or 
dependent variables individually,  
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(2) The researcher is interested in the relationships among the p variates (where p = 
number of dependent variables, as in the example above),  
(3) The researcher wishes to reduce the p variates to some smaller set of 
psychological, physiological, or theoretical dimensions, and/or  
(4) The researcher is interested in the set of measures as they represent some 
underlying construct(s) or dimension(s) (Bray & Maxwell, 1982).  
By examining several variables together, MANOVA may provide a more powerful 
test than doing separate ANOVAs (Bray & Maxwell, 1985, p. 11) as the vector 
representation of a combination all dependent variables is compared across groups 
which may combine otherwise small differences between dependent variable group 
means. In this chapter, the aforementioned reasons for using multivariate statistics will 
be examined more deeply in the context of their respective statistical methods in 
relation to MANOVA. Overall, it is important to balance statistical considerations with 
philosophical, theoretical or practical ones as a mis-match of the method of data 
analysis with the questions asked may complicate or even distort interpretation of the 
results, and the conclusions drawn may be incorrect (Biskin, 1980). 
MANOVA 
MANOVA is a powerful statistical technique allowing for several dependent 
measures to be analysed simultaneously (Spector, 1977) and its continued proliferation 
can no doubt be attributed to the belief that models of nature and human behaviour 
must often account for multiple, inter-related variables that are conceptualized 
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simultaneously or over time (Grice & Iwasaki, 2007).  The goal in MANOVA is to 
maximally discriminate between two or more distinct groups on a linear combination of 
quantitative variables treated simultaneously while recognizing their potential inter-
relatedness (Grice & Iwasaki, 2007). This procedure combines all dependent variables to 
create an optimally weighted canonical or super variable, thereby avoiding problems 
with choosing one of a number of possible dependent measures to represent a 
multivariate concept (Spector, 1977).  
 Like ANOVA, MANOVA is a two-stage process wherein a primary omnibus test is 
conducted to determine the main effects and interactions of the multivariate 
hypotheses, followed by subsequent tests to ascertain which of the p dependent 
variables are accounting for these effects (Spector, 1977). It tests the existence of at 
least one linear combination of the responses which will reject a null hypothesis of no 
experimental effect (Wilkinson, 1975).  
In MANOVA, the null hypothesis is an extension from the null hypothesis in ANOVA 
with the purpose to compare population means, or group centroids (analogous to a 
univariate group mean) for k groups across p variables (where k represents the number 
of groups). In other words, the null hypothesis is that for each variable, all k group share 
the same population mean (Bray & Maxwell, 1985, p. 15) which is calculated based on 
all assessed dependent variables. The alternative hypothesis in this case is that for at 
least one variable, there is at least one group with a population mean different from the 
others (Bray & Maxwell, 1985, p. 15).  
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Mathematical Basis of MANOVA 
ANOVA, as explained below (see mathematical basis of ANOVA), is based on a 
comparison of variance attributed to the treatment (dependent variable) and 
unaccounted for as error for three or more groups. This variance is termed the mean 
square and is based on a ratio of the treatment and error sum of squares (SST and SSE 
respectively) to their respective degrees of freedom. Together, the ratio of the 
treatment and error mean squares creates the F-ratio used in interpreting the test (see 
Table 6 : Independent Groups One-Way ANOVA Summary Table). 
MANOVA however is more complicated as multiple dependent variables are 
involved, which requires consideration not only with each uni-dimensional variance (ie. 
variance for a single dependent variable as calculated in ANOVA), but also the 
relationship between the dependent variables (Bray & Maxwell, 1985, p. 20). As such, 
this relationship is captured in the product of each sum of squares for the treatment and 
error variance components computed in a matrix called a sum of squares and cross-
products (Bray & Maxwell, 1985, pp. 20–21). The resultant treatment and error matrices 
can be quite complex to interpret as they consist of p2 elements (Bray & Maxwell, 1985, 
p. 22). This is where discriminant function variates, each of which represents a linear 
combination of the original variables (Bray & Maxwell, 1985, p. 24), comes into play in 
terms of interpretation.  
The first discriminant function variate to be created and assessed is the 
circumstance where the linear combination of the original variables maximizes the ratio 
of SST/SSE. In general for k groups and p dependent variables, the total number of 
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discriminant function variates, denoted by s, which will be created, equals the smaller of 
k-1 and p (Bray & Maxwell, 1985, p. 24). Together, the s discriminant function variates 
completely account for all of the between-group variation in the sample (Bray & 
Maxwell, 1985, p. 24).  
Test Statistics 
Four separate F-statistics; Pillai-Barlett Trace, Hotelling-Lawley Trace, Wilks’ Lambda 
and Roy’s Greatest Characteristic Root (GCR), are generated for a given MANOVA. These 
values are used to ascertain how large the s eigenvalues (where s denotes the number 
of eigenvalues) are in comparison to their respective expected values if the null 
hypothesis was true (Bray & Maxwell, 1985, p. 27).  Choosing which test statistic to 
employ involves a complex consideration of the robustness and statistical power 
associated with each test (Bray & Maxwell, 1985, p. 28). The first three statistics (Pillai-
Barlett Trace, Hotelling-Lawley Trace, and Wilks’ Lambda) differ from Roy’s GCR by 
combining, in some manner the information for all of the discriminant functions 
produced from the analysis for a given effect (Grice & Iwasaki, 2007) while Roy’s GCR 
looks only at the first discriminant function created. Wilks’ Lambda is useful for 
determining the effect size for a test and is historically the most widely used of the four 
approaches (Bray & Maxwell, 1985, p. 28) and the Pillai-Barlett trace for MANOVA is  
consistently more robust to assumption violations across a wide range of population 
configurations in comparison to the other three statistics, sometimes by a substantial 
margin (Olson, 1976, 1979).  
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Assumptions 
Though MANOVA is fairly robust to perturbations of normality and variance given 
equal sample sizes (Mardia, 1971), some assumptions must be accounted for including: 
1) independence of observations, 2) multivariate normality of the group population 
dependent variables, and 3) homogeneity of group population variance-covariance 
matrices (Grice & Iwasaki, 2007). 
Independence of Observations 
Independence of observations refers to the dependence of observations upon each 
other and is measured by the intraclass or Pearson correlation. This is an important 
assumption to qualify as correlated data between individuals will increase the true type 
I error probability and decrease the true type II error probability (see Table 5) for an F-
test, particularly as the number of treatments and sample size increases (Scariano & 
Davenport, 1987). To assess the degree to which this assumption has been met, data 
should be recorded in the order of collection with a corresponding case number. Each 
dependent variable should then be regressed onto the case identification number to 
create the intraclass or Pearson correlation. A statistically non-significant value indicates 
independence of observations. 
Normality 
Given similar sample sizes (ie. largest n is no more than 1.5X greater than the 
smallest n), and error degrees of freedom are >20, violations of normality or 
multivariate normality have very mild effects on alpha (Mardia, 1971). Univariate 
normality is necessary, but not sufficient for the multivariate normality (Carroll, 1961) 
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which generally, is more restrictive as both the sampling distributions of the dependent 
variable means, as well as all their linear combinations, must be normally distributed. 
Measures of normality may be completed using a Shapiro-Wilk W tests where a 
significant result indicates non-normality. Given a statistically significant Shapiro-Wilk 
test, skewness and kurtosis descriptive statistics may then be examined to determine 
where the non-normality exists. Typically, a skewness or kurtosis statistic that is twice 
the absolute value of its respective standard error is considered to be non-normal. 
Though typically not a problem, issues of normality can be combated with data 
transformation. 
Homogeneity of Covariance (Homoscedasticity)  
Homogeneity of covariance, or homoscedasticity, is the property of having equal 
variances as calculated between groups. It is not typically a concern in terms of altered 
type I or type II error when interpreting univariate or multivariate analyses of variance 
(Hakstian, Roed, & Lind, 1979), especially with equal sample sizes. Box’s M is a very 
conservative test used for assessing homoscedasticity and may be ignored with equal 
sample sizes but should be evaluated using the α=0.001 level with dissimilar sample 
sizes. Levene’s Test of Equality of Error Variances tests the null hypothesis that the error 
variance of the dependent variable is equal across treatment (independent) groups. This 
test should also be evaluated in completing a MANOVA at the p=0.05 level. Significance 
on this test indicates heterogeneity in variance. In the case of unequal sample sizes, if 
the larger variance is associated with the smaller sample, the F-ratio is liberal whereas if 
it is associated with the larger sample, the F-ratio is conservative. Given the robustness 
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of MANOVA to variance and normality (Mardia, 1971) this is typically not a problem in 
tests of equal sample size. 
Singularity, Multicollinearity and Independence 
Multicollinearity refers to the circumstance under which dependent variables are 
highly intercorrelated and singularity, when variables have perfect correlation, is the 
extreme case of multicolinearity. Data under consideration in a MANOVA should possess 
some amount of multicollinearity as multivariate tests statistics should form the basis 
for decision making whenever criterion variables are aspects of the same construct 
(Finn, 1974, p. 320), but attention should be given to extreme correlations. It is 
important to understand the dependent variables being combined and assessed as a 
canonical variate in a MANOVA to ensure that issues of multicollinearity and singularity 
do not result from too great of a correlation. For instance, with two highly correlated 
dependent variables, one variable may be assessed to have a large discriminant 
coefficient and the other a small one with the weights being divided somewhat 
arbitrarily (Kaplan & Litrownik, 1977) which contributes to high variability in the 
discriminate function coefficients (Grice & Iwasaki, 2007) and complicates the 
interpretation of the multivariate effect. Commonly accepted multicollinearity levels for 
MANOVA are 80-90% (Grice & Iwasaki, 2007). 
Missing Data 
Missing data can be a big problem in MANOVA as incomplete data sets cannot be 
analysed. The most common approach in statistical programs to deal with missing data 
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is to delete the subject with missing data entirely from the analysis (Twisk & De Vente, 
2002), in a procedure called list-wise deletion. In considering why data is missing and 
the nature of the missing pieces (ie. systematically or at random), a researcher may 
choose to deal with missing data in a number of ways. This may include cross-sectional 
methods: mean substitution and cross-sectional linear regression, and/or longitudinal 
methods: last value carried forward, linear interpolation imputation, individual 
longitudinal regression imputation and population longitudinal regression (Twisk & De 
Vente, 2002).  
Any of the aforementioned procedures to manage missing data are acceptable, 
though a researcher should report the amount, nature and method of substituted data 
as well as justification for having done so.  
Outliers 
MANOVA is primarily concerned with multivariate outliers, as opposed to univariate 
outliers, as the variables under consideration are numerous and correlated. As such, the 
approach of using a box-plot to denote outliers in ANOVA (see Figure 19) is not useful 
here. An accepted method of determining outliers is calculating Mahalanobis distance 
scores for each subject and denoting subjects with a Mahalanobis distance score greater 
than a chi-square value with degrees of freedom = number of independent variables at 
p=0.001 as an outlier.  
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Table 4: Chi Square Table for Common df Values 
df p = 0.05 p = 0.01 p = 0.001 
1 3.84 6.64 10.83 
2 5.99 9.21 13.82 
3 7.82 11.35 16.27 
4 9.49 13.28 18.47 
5 11.07 15.09 20.52 
6 12.59 16.81 22.46 
7 14.07 18.48 24.32 
8 15.51 20.09 26.13 
9 16.92 21.67 27.88 
10 18.31 23.21 29.59 
Statistical Power 
Statistical power is the probability of rejecting the null hypothesis when it is false 
and must be achieved to determine if a statistically significant effect is present. Stevens 
(1980) presented several findings related to power and MANOVA for the social sciences. 
His main conclusions suggest that as p increases, it is necessary to increase sample size 
to maintain a given level of power for a specified effect size (Stevens, 1980). Thus it is 
wise to limit the number of dependent variables to a reasonably small number (eg. 10 or 
fewer) unless sample sizes are quite large (Bray & Maxwell, 1985, p. 34). The power of a 
given MANOVA statistic is also dependent on correlations between the dependent 
variables and may result in increased or decreased power in comparison to separate 
ANOVA tests (Bray & Maxwell, 1985, p. 35).  
Table 5: Statistical Power and Error types 
 Fail to reject HO Reject HO 
HO true CORRECT (α) Type I error 
HO false (β) Type II error POWER 
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Estimates of Effect Size - η2 
As in ANOVA, the meaningfulness of a statistically significant result is not evidenced 
by its significance level as trivial differences may appear significant in large sample sizes 
while meaningful differences may be masked by small sample sizes (Bray & Maxwell, 
1985, p. 36).  Reporting effect sizes helps to standardize the magnitude of an effect 
regardless of sample size and describes how strongly two or more variables are related, 
or how large the difference between groups is (Levine, 2002).  
One effect size commonly reported in MANOVA-based literature is eta-squared (η2) 
which “is interpreted as the proportion of the total variability in the dependent variable 
that is accounted for by variation in the independent variable” (SPSS for Windows, 9.0 
help menu, as referenced by Levine, 2002). It may be calculated as 1 – the Wilk’s 
Lambda MANOVA test statistic. “When there is one degree of freedom in the numerator 
(treatment MS), the square root of eta squared equals r… when there is more than one 
degree of freedom in the numerator, eta squared equals R2” (Levine, 2002). In SPSS, a 
partial-η2 is typically reported as an estimate of effect sizes for a given test. This is 
different than an overall η2 as it considers only the variability associated with the 
treatment and error, which is different from the total error used in the η2 calculation 
when the error is parsed into systematic and unsystematic error in a dependent groups 
scenario. Partial η2 is at least equal to or greater than η2 which can lead to inflated 
attribution of variability if it is not interpreted correctly. This effect is magnified with 
increased groups assessed (Levine, 2002). Partial η2 is however useful if one wishes to 
compare the size of an effect of an identical manipulation across studies with different 
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designs, as it  may prove more comparable than η2 (Levine, 2002). Partial η2 describes 
the partial proportion of the variance explained in the dependent variable explained 
uniquely by the variable of interest divided by the proportion of variance in the 
dependent variable unexplained by the other variables (Levine, 2002). Since all ANOVA 
comparisons in this thesis are one-way in design, partial η2 will be reported as it is 
equivalent to η2 in this case (Levine, 2002).  
Challenges with MANOVA 
Though MANOVA may serve as a statistical aid with correlated and multivariate 
data, some challenges are associated with its use. For instance, uncorrelated dependent 
variable criteria (eg. stork population and human birth rate) and a small sample size 
disadvantage the statistical power of the test (Bray & Maxwell, 1985, p. 12). The results, 
especially after the primary omnibus test are also typically more complex and difficult to 
interpret than univariate analyses (Bray & Maxwell, 1985, p. 12). 
Post MANOVA analyses 
“Simplification and the interpretation process is perhaps the most important stage 
of the MANOVA since it provides the bridge from a purely statistical effect to a 
theoretically meaningful effect” (Grice & Iwasaki, 2007) and, while the mathematical 
basis for applying MANOVA is well-known (Bock, 1975; Finn, 1974), there is little 
consensus as to the "proper" methods for further analyzing and interpreting group 
differences after a significant MANOVA F-test is realized (Borgen & Seling, 1978; Kaplan 
& Litrownik, 1977; O’Grady, 1978; Spector, 1977; Stevens, 1972; Wilkinson, 1975). 
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Typically, researchers have two general categories of secondary analyses, univariate and 
multivariate, to further parse out where specific variability lies in their dependent 
variables. Multiple univariate F-tests or ANOVAs following a MANOVA offer the 
capability for univariate conclusions to be drawn, while discriminant analysis and step 
down analysis allow the originally multivariate analysis to continue as such into 
multivariate conclusions. It is a misconception that outcomes from multivariate analyses 
are simply additive functions of the results from univariate analyses (Grice 2007).  
Reviews completed by Stevens (1972) and Wilkinson (1975) examined the use of these 
three methods (univariate F-tests, discriminant analysis and step-down analysis), as well 
as a fourth (two group breakdown -- which is quite similar to discriminant analysis), and 
arrived at similar conclusions stating that no one approach was necessarily superior to 
the others (Spector, 1977) but the choice as to which one to use is highly dependent 
upon the questions being asked and the nature of the data being analysed. Of particular 
interest is the correlative nature of the data as uni- or multivariate tests account for and 
deal with correlated data in different ways, thereby affecting the obtained results. 
Figure 18 (Stevens, 1972) illustrates a breakdown of possible forms statistical analysis 
after a significant MANOVA. Of these analysis types, two-group breakdowns (via 
ANOVA), discriminant analysis and step down analysis will be further examined. The 
choice to use either uni- or multivariate analyses must be grounded in theory and an 
understanding of the questions being asked and should be made explicit and justified by 
the investigator (Biskin, 1980; Huberty & Morris, 1989). 
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Figure 18: Schematic breakdown for the K-group MANOVA problem from Stevens 1972.  
Used with permission from Routledge, Taylor & Francis Group 
Univariate Analyses 
Experimenters using MANOVA usually want to analyze effects separately for each 
response variable after rejecting a null hypothesis of multivariate dispersion (Wilkinson, 
1975). Also, regardless of whether MANOVA is employed as a primary step in 
determining treatment effects in multivariate data, or not completed at all, the most 
common approach to multivariate data analysis is a series of univariate comparisons 
(Kaplan & Litrownik, 1977). As this analysis type is based on ANOVA, the following 
section will detail the mathematical and assumption constructs of ANOVA, and will be 
followed by a discussion on how to interpret a series of ANOVAs and its limitations in 
relation to a previously conducted statistically significant MANOVA. 
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ANOVA 
ANOVA, or analysis of variance, test statistics are typically used to compare k groups 
across a single dependent variable. It combats the issue of multiple comparison bias and 
inflated type I error associated with conducting multiple t-tests (two-independent group 
comparisons) for a single dependent variable. The null hypothesis for ANOVA is that all 
sample means are equivalent, and the alternative hypothesis is that at least one pair of 
means differ. ANOVA is an omnibus test looking at the whole of the treatment effect at 
once, instead of separate two-group comparisons, and thus if significant, does not 
indicate where variance lies between specific paired groups. Discerning where this 
significance lies requires an a priori analysis or post hoc analysis, such as a Tukey’s 
Honestly Significant Difference (HSD).  
Mathematical basis of ANOVA 
ANOVA is based on the comparison of the variance for three or more groups which 
is derived from their respective treatment and error sums of squares (SS) as well as their 
treatment and error degrees of freedom (df). Sum of squares refers to the sum of 
square deviations about the mean which describes the variability inherent to a given 
data set. Degrees of freedom refer to the number of values that are free to vary, given 
any restrictions imposed by the design. For example, in multiplying a set of numbers, all 
but one number are free to vary infinitely so long as the final value can be proscribed in 
order to produce a desired value.  
The ratio of a sum of squares to its respective degrees of freedom (SS/df) is called a 
mean square and is a variance estimate. The mean square values for treatment and 
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error are then combined in a ratio (treatment/error) to determine the F-ratio for the 
test. If the F value is sufficiently larger than 1, decided using the corresponding critical F-
ratio, it can be concluded that there is a significant omnibus effect. To determine the 
appropriate critical F-ratio to use, the treatment and error degrees of freedom are used 
in conjunction with a specified alpha level to find the appropriate value on a table of 
critical F values (see Appendix A). The null hypothesis should be rejected if the F-ratio 
obtained is greater than the corresponding critical F-ratio. Table 3 summarizes the 
calculations required to complete an independent groups one-way ANOVA. 
Table 6 : Independent Groups One-Way ANOVA Summary Table 
Source SS df MS F 
Treatment ∑  
 
   
( ̅   ̅ )
  k-1 
   
   
  
Error ∑(    )  
 
 
   
 N-k 
   
   
 
   
   
 
Total SST + SSE N-1   
 
The calculations for a one-way, dependent groups, ANOVA are similar to those 
explained above for the independent group case, though the SSE and degrees of 
freedom Error terms are split into two pieces to separately account for systematic and 
unsystematic error. This division of error in a dependent groups case allows for a greater 
proportion of the error term to be accounted for as systematic error by removing 
subject variance, and thus increases the power of the test leaving just the unsystematic 
error variance term as the denominator. 
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Assumptions 
Like MANOVA, ANOVAs require several assumptions to be qualified before their use. 
The major assumptions are independent observations, normality, and variance. 
Regarding variance, homogeneity of variance must be addressed in the independent 
case or circularity of variance in the dependent case. Each of these assumptions, to the 
exception of circularity of variance, has been previously described in detail in the 
MANOVA assumptions section. The only difference to note is that the concern in ANOVA 
is solely on univariate comparisons and thus multivariate concerns like homoscedasticity 
(in independent ANOVA it is simply variance) do not apply. For dependent ANOVAs, 
circularity can be assessed using Mauchly’s test of sphericity, which is an estimate of 
circularity. In all, despite having these assumptions to satisfy prior to competing an 
ANOVA statistic, it should be noted that for equal sample sizes, ANOVA is robust to 
violations of normality and variance (Mardia, 1971). 
Outliers and Missing Data  
In ANOVA, outliers can be determined using a box-plot for each group on the 
measured dependent variable. Box-whisker plots display descriptive statistical 
information about the data set including mean, median, interquartile range (IQR), 
maximum and minimum non-outlier values as well as outliers (see Figure 19). 
Traditionally, an outlier is defined by ± 1.5 (IQR), and extreme outliers by ± 3 (IQR). On a 
box plot, outlier values are denoted by dots outside of the whiskers with their subject 
identification number noted beside. 
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Missing data in ANOVA can be dealt with in the same way as previously described for 
MANOVA as long as the method of choice and nature of the data are explained and qualified.  
 
Figure 19: Box-Whisker Plots 
Effect Size Estimates in ANOVA 
Effect size estimates, as in MANOVA, are important to include along with 
significance values. Examples of effect size include: eta-squared, omega-squared and 
epsilon-squared. Eta-squared has been explained above (see Estimates of Effect Size - 
η2) though estimates of each effect size type differ only slightly with moderate or large 
sample sizes (Levine, 2002).  
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Post ANOVA testing: Post Hoc or A Priori 
As mentioned, the primary omnibus portion of the ANOVA statistic does not detail 
where statistically significant differences exist, so follow-up analyses, either of the post 
hoc or a priori fashion, must occur.  
A priori comparisons are planned comparisons which are done instead of ANOVA. If 
the specific hypothesis in question was developed before the data were collected, then 
an a priori test is appropriate instead of conducting an ANOVA as it will be a more 
powerful assessment. If however, the goal is to test all possible comparisons, a post hoc 
test is appropriate.  
Many post hoc tests can be calculated by statistical software programs, such as SPSS, 
though the most commonly reported is Tukey’s HSD. It is essentially a method for 
computing multiple t-tests while controlling for the inflation of Type 1 error that follows 
the use of multiple comparisons. A note of caution with reporting Tukey’s HSD value (q) 
from SPSS outcomes is to ensure that the standard error in the output is divided by √  
before it is reported. SPSS calculates the q-statistic in a Tukey’s HSD calculation 
differently than it is conventionally done ad as a result must be adjusted by a factor of 
√ .  
Multiple Univariate F Statistics  
With a seemingly greater preference for the interpretation of univariate as opposed 
to multivariate analyses in the literature, potentially for their relative ease of 
computation or interpretation, or due to a lack of familiarity with the statistic (Biskin, 
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1980), many researchers choose to follow a statistically significant MANOVA with a 
series of univariate analyses of variance (ANOVAs) to assess the extent to which there is 
a statistically significant effect for each dependent variable individually. Each univariate 
F ratio that reaches the specified alpha level is considered statistically significant and 
available for interpretation (Bock, 1975) and each of these univariate tests are 
insensitive to the correlations among the variates (Bray & Maxwell, 1982; Spector, 
1977). Separate F statistics for each of the outcome measures provide useful descriptive 
data. For any one hypothesis, the largest single-variate F ratio is obtained for the 
variable having the largest between-group difference, relative to within-group variation 
(Finn, 1974, p. 320; Spector, 1977). Also, multiple univariate F ratios can also provide 
relative strength-of-effect estimates for the outcome measures (Finn, 1974, p. 320).  It 
should be noted, however, that separate F statistics for variables that are correlated are 
not independent of one another and should not be used as partial tests of multivariate 
hypotheses (Bray & Maxwell, 1982; Finn, 1974, p. 320). The actual magnitude of group 
mean differences may also be clouded here as relationships and common variance 
between variables are ignored (Spector, 1977). 
Multiple univariate F-tests should be used if the dependent variables are 
conceptually independent from each other or as a first step in a replicated study design 
to decrease the number of dependent variables used for the final multivariate test and 
increase power (Biskin, 1980). It may also be used to generate results for comparison 
with previously analysed or published data (Huberty & Morris, 1989) or in simple 
hypothesis testing of individual variables (Spector, 1977).  
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MANOVA, Univariate F-Tests and Type I Error:  
Hummel and Sligo (1971) demonstrated in a series of Monte Carlo simulations, 
which investigated various numbers of criteria, sample sizes and within-groups 
correlations, that all univariate ANOVAs conducted on data previously run through a 
MANOVA obtaining a significant result operate under a “protected-F”. According to 
Hummel and Sligo, this protected F approach adequately controls the experiment-wise 
(ie. error across all statistical tests performed as opposed to test-wise) error rate near 
the nominal alpha level (Bray & Maxwell, 1982) suggesting that a correction factor, such 
as a Bonferroni  or modified Bonferroni adjustment to control type I error (Grice & 
Iwasaki, 2007) need not be applied to the series of analyses as type I error is protected 
from inflation. Much controversy over the validity of this publication exists. Miller 
(1966) concludes that the preliminary F test guards against falsely rejecting the null 
hypothesis when the null hypothesis is true (Miller, 1966, as referenced by Bray & 
Maxwell 1982). However, when, in fact the null hypothesis is false and likely to be 
rejected, the second stage of the least significant difference gives no increased 
protection to that part (if any) of the null hypothesis which still remains true (Bray & 
Maxwell, 1982).  
Challenges with Multiple Univariate F Statistics 
In a sense, while using multiple univariate F statistics as a form of analysis is justified 
in some cases, using MANOVA as a gate-keeper to create a protected-F in subsequent 
analyses or only reporting univariate effects for multivariate data obscures the initial 
advantage of the MANOVA technique (Kaplan & Litrownik, 1977) in gaining an 
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understanding of the interesting and interpretable multivariate effects and correlative 
implications of the data. Multivariate information from a MANOVA is contained in the 
linear combinations of dependent variables that are generated from the analysis. 
Conducting an ANOVA on each of the dependent variables following a MANOVA 
completely ignores these linear combinations (Grice & Iwasaki, 2007) and may result in 
difficulty drawing conclusions or even arriving at a mislead conclusion (Biskin, 1980). 
Also, the conceptual meaning of the results from a series of ANOVAs will not necessarily 
match the conceptual meaning of the results from a MANOVA (Grice & Iwasaki, 2007) as 
groups may be significantly different in a multivariate sense, while all univariate tests 
are non-significant or visa-versa. “Without knowing the correlations among the 
dependent measures, it is impossible to judge from univariate results whether or not a 
real difference exists among experimental groups with a specifiable level of confidence” 
(Biskin, 1980).   
Multivariate Statistics: 
Continuing with a multivariate analysis after a statistically significant MANOVA offers 
the benefit of conceptualizing the canonical variable as whole, including dependent 
variable interactions, instead of each part separately. Two forms of analysis: 
discriminant analysis and step-down analysis will be discussed in this section. These 
methods allow primarily for group separation and classification as well as assessment of 
dependent variable interrelations in the discriminant case and for variable selection and 
ordering as well as variance attribution in the step down case. 
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Discriminant Analysis 
Discriminant analysis, developed by Fisher (Fisher, 1936), is a mathematical 
maximization procedure (Stevens, 1972) with the purpose to specify the linear 
combination of p variables that maximizes the differentiation between or among k 
treatment or pre-existing groups (Spector, 1977).  It provides a breakdown of 
association with each function expressed as a canonical variate. Discriminant functions 
are generated using the sum of squares and cross-product matrix as mentioned in “the 
mathematical basis of MANOVA section” as discriminant functions lie at the heart of a 
MANOVA statistic. 
Discriminant analysis is appropriate for the following four purposes: 1) separation 
between k groups, 2) discrimination of dimensions and variates, 3) estimation of the 
relationship between the s variates and k group membership variables, and 4) classifying 
individuals to specific populations (Huberty, 1975). The main strength of this technique 
by itself is in prediction and classification and, in conjunction with step-down analysis, in 
choosing subsets of the original p variables for future use (Spector, 1977). When 
interpreted together with univariate ANOVA results, discriminant scores may provide 
information on the interrelation between dependent variables.  
Most commonly, discriminant functions are interpreted using the discriminate 
function standardized coefficients which represent the relative contribution of the 
variable to the discriminant function (Bray & Maxwell, 1982; Huberty, 1975; Stevens, 
1972) which are influenced by intercorrelations between dependent variables (Bock, 
1975; Bray & Maxwell, 1982; Finn, 1974). 
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Discriminant Scores 
As aforementioned, “discriminant analysis yields a series of transformation vectors 
which can be applied to the original measures to produce discriminant scores” which 
represent a summation of all dependent variables across each subject (Kaplan & 
Litrownik, 1977). Each dependent variable is multiplied by its corresponding 
discriminant weight and summed for an individual to obtain a subject’s discriminant 
score. These discriminant scores can be used to ascertain which variables have the 
greatest association with the discriminant function where variables with larger 
associations have larger discriminant scores. Another way of assessing the relative 
importance of each variable in relation to each discriminant function is to compute the 
standardized discriminant function coefficients which may be obtained by multiplying 
the coefficient of each standardized discriminant function by the standard deviation of 
the original variable associated with that coefficient (Stevens, 1972).   
As mentioned, multicollinearity can be an issue in discriminant analysis. For 
example, if two variables are highly correlated, the relative importance of the variables 
must be divided between the two, which can be relatively arbitrary (Bock, 1975; Bray & 
Maxwell, 1982).  
Challenges with Discriminant Function Analysis 
Discriminant function coefficients are highly sample dependent. This means that a 
change in the variables included, or even individual subject values used can disrupt a 
coefficient value (Stevens, 1972) and thus, caution should be exercised in interpreting 
results of tests with small sample sizes (Spector, 1977). Also, since discriminant function 
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coefficients are influenced by intercorrelations between dependent variables (Bock, 
1975; Bray & Maxwell, 1982; Finn, 1974), which may skew the value of their actual 
relative contribution, they cannot be interpreted independently. Lastly, when there are 
more than one statistically significant discriminate function variates, the analysis 
becomes very complicated to interpret. As a result of these limitations, discriminant 
analysis was not selected for use in the examination of MSNA variables for this study. 
Step-down Analysis 
If the dependent variables are correlated, which they should be in a MANOVA, step-
down analysis can be applied. Step-down analysis was developed by Roy (Roy, 1958) and 
is used to identify unique variability among dependent variables whereby each variable 
is tested with the previously accounted for variability from other variables taken into 
account. Simply put, dependent variables are ordered on a theoretical basis to list the 
most important variable first and then the remaining dependent variables serially in 
ANCOVAs. This adds the previously tested dependent variables to the analysis as 
covariates allowing the researcher to determine the between-group effect for the first 
criterion measure, for the second criterion measure, eliminating the first; for the third 
eliminating the first two; and so on. (Finn, 1974, p. 322). Since variables are sequentially 
removed from the analysis, their order of analysis matters which should be carefully 
considered from a theoretical standpoint and should be thought of in an a priori fashion 
(Bray & Maxwell, 1982). With each step in this analysis, an effect size measure, should 
be reported as it reflects the variability attributable to that variable with covariates 
(previously tested variables) removed. A large drop in effect size between 2 subsequent 
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steps would indicate that the removed variable is an important component of the 
multivariate composite (Grice & Iwasaki, 2007). Issues of Type I error must be 
confronted with step-down tests since there are multiple significance tests which may 
be performed and thus a Bonferroni or modified Bonferroni adjustment is 
recommended (Bock, 1975; Bray & Maxwell, 1982). Typically, stepwise analyses have 
been used for three purposes: 1) selection or deletion of variables, 2) assessing relative 
variable importance or 3) both variable selection and variable ordering (Huberty & 
Morris, 1989). 
ANCOVA 
ANCOVA is rarely more powerful than ANOVA and was introduced by Fisher in 1932 
as a means for reducing error variation and increasing the sensitivity of an analysis to 
mean differences (Finn, 1974, p. 368).  By including covariate measures in the statistical 
test, residual variation can be reduced through its attribution to covariates where 
intercorrelation exists (Finn, 1974, p. 369). From a basic standpoint, in ANCOVA or 
MANCOVA, a univariate or multivariate analysis of variance is computed with the 
addition of a covariate which parses out some of the variability from the dependent 
variables to the extent that it is attributable to the covariate. The resulting statistic then 
reflects the contribution of the dependent or canonical variable (uni- or multivariate 
respectively) with the covariate’s variability removed.  
Challenges with Step-down Analysis 
A basic issue with step down procedures is its consideration of variables one-at-a-
time which prohibits the use of tests for additional information supplied by other 
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variables (Huberty & Morris, 1989). Poor selection of the order for analysis is also 
problematic in step-down analysis as all subsequent variables are affected. It is not easy 
to determine what the best subset of variables is (Huberty & Morris, 1989) which is why 
a strong pedagogical and theory based decision must be made.  
Conclusions 
Quoting R.A. Fisher, “statistics is quantified common sense”. As such, data should be 
carefully examined, using multiple analyses and sound judgement (Huberty & Morris, 
1989). 
MANOVA offers a rich and powerful technique for analysing multivariate data. 
Though assessing multivariate effects are typically a greater challenge for computation 
and interpretation in comparison to their univariate counterparts, being able to 
comment on a canonical effect of correlated dependent variables and parse out where 
true variance lies is key. It is up to the researcher to ensure that the statistical tests 
employed adequately satisfy the questions asked and that all assumptions are 
reasonably accounted for.   
After a statistically significant MANOVA there are several options for further 
analysis. Three options: multiple univariate F-tests, discriminant analysis and step down 
analysis have been discussed here. Each type of analysis has its merits and should be 
considered when assessing multivariate data. Table 7 summarizes key strengths and 
weaknesses of each post-MANOVA analysis which should be considered in choosing a 
statistic. 
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Table 7: Summary of Indications, Benefits and Challenges associated with Post-MANOVA 
Analyses 
Statistic Indications Benefits Challenges 
Univariate 
F-tests 
Hypothesis testing in 
conceptually uncorrelated data 
Simple statistical 
method 
Ignores correlations in 
data 
Discriminant 
Analysis 
group separation & 
classification, and assessment 
of dependent variable 
interrelations 
True multivariate 
consideration of 
dependent variables 
Challenging to 
interpret, very sample 
dependent 
Step Down 
Analysis 
variable selection & ordering, 
and variance attribution 
Allows for parsing out 
of variance using 
sequential ANCOVAs 
A priori ordering is 
necessary, assesses 
variables somewhat 
independently 
For this thesis, the statistical concentration is on a modified MANOVA-Step down 
approach to determine where variability lies in relation to multivariate muscle 
sympathetic nerve activity (MSNA) data. In practice, of the numerous quantifiable MSNA 
parameters, burst frequency (bursts/min) and burst incidence (bursts/100hb), are 
typically reported in the literature as the sole measure(s) of MSNA. However, new 
methods are providing more variables. Since all measureable variables are correlated 
and together represent the overall concept of MSNA, it seems reasonable to evaluate 
the dependent variables as a unit. For this analysis, after a successful MANOVA, the 
significance of each variable separating  groups will be evaluated and used to determine 
components of a subsequent MANCOVA comparing integrated and AP variability 
attributions.  
Chapter 3 will address the MANOVA-step down analysis of baseline MSNA data in 
comparing young and old healthy groups and Chapter 4 will address the comparison 
between groups of young, old, metabolic disease, coronary artery disease and 
congestive heart failure (class I and II) individuals.  
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Chapter 3: 
Methodology and Results 
Chapters 1 and 2 focussed on general background information pertaining to MSNA 
and the SNS as well as MANOVA methods. As evidenced throughout, an emerging 
challenge facing SNS researchers is determining which MSNA variables to measure and 
subsequently report to describe MSNA characteristics and differences between groups, 
and MANOVA, as a statistical tool, may help solve this problem. Given the large number 
of MSNA variables available for interpretation and analysis, as discerned from the 
filtered and integrated neurograms, this study tested the hypothesis that newly 
available action potential information would better discriminate groups than the 
traditional integrated variables of burst frequency and burst incidence. As such, the goal 
was to ascertain which MSNA variables account for the most variability in a group 
difference and then use these proscribed variables to help describe physiological 
differences between groups of differing age or CVD. We tested the hypothesis that AP 
variables would better differentiate between groups than traditional integrated 
variables.  
Using ten variables collected on baseline MSNA, two group comparisons were made 
to assess the effects of age (n= 37) and CVD (n=34). These variables included: burst 
frequency, burst incidence, mean burst area, mean burst area/min, burst latency and 
burst amplitude, as well as spikes/min, spikes/100hb, spikes/burst and clusters/burst. 
MSNA data were collected using the microneurography technique (Hagbarth & Vallbo, 
1968) at the common peroneal nerve. Both the integrated and filtered neurograms 
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were analysed to provide the mentioned ten variables. These variables were collectively 
assessed in a MANOVA to discriminate between groups and then, following a significant 
MANOVA, determine via univariate ANOVAs which variables should be analysed further. 
These variables were then assessed via a MANCOVA to determine their respective 
amounts of variability and will be described in relation to age, health and disease in 
Chapter 4.  
Methods 
Subject Characteristics 
For the age comparison, 18 young and 19 old files were used. For the CVD state 
comparison, 7 young (6 from the age comparison), 7 old (all from the age comparison), 8 
metabolic syndrome (Met), 7 coronary artery disease (CAD) and 6 chronic heart failure – 
class I (n=2) and class II (n=4) (CHF) files were used. Average anthropometric, health 
status and baseline cardiovascular measures for participants are displayed in Table 8 
and Table 9 for the age and CVD state comparisons respectively. Statistically significant 
comparisons are noted with F-values, significance levels and estimates of effect size. 
One Met file was excluded from analysis as it was determined to be an outlier using 
Mahalanobis distance scores for the physiological data.  
A two-pronged approach to analysis was completed to assess statistical differences 
between group anthropometric, cardiovascular and age data. Specifically, a MANOVA 
followed by variable specific ANOVAs. F-values, significance level and partial η2 values 
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(effect size estimates) are reported for each comparison in Table 8 and Table 9 
respectively. 
For the Age comparison, Box’s test of equality of covariance matricies was not 
statistically significant. A significant MANOVA, F(6,30)=51.495, p<0.001, partial 
η2=0.911. Levene’s test for equality of error variances was significant for the age 
variable however, since sample sizes are equal this is not a concern. Statistically 
significant ANOVAS were found for the Age, SBP and DBP variables as illustrated in Table 
8 . Appendix C contains a table with full descriptive statistics on the age comparison.  
Table 8: Mean Young and Old Anthropometric, Vitals and Health Status Data – Age Comparison 
 Young (± SD) Old (± SD) Statistical Difference 
n 18 19  
Age (years) 24 (± 3.5) 59 (±8.3)* 
F(1,35) = 278.28, p>0.00, 
partial η2=0.888 
Sex (M:F) (7:11) (10:9)  
SBP (mmHg) 112 (± 12.7) 124 (±17.7)* 
F(1,35) = 5.68, p=0.023, 
partial η2 = 0.140 
DBP (mmHg) 67 (± 8.6) 73 (± 9.3)* 
F(1,35) = 4.532, p=0.040, 
partial η2 =0.115 
RHR (bpm) 61 (± 7.7) 61 (± 11.6)  
Medications BCP (n=4) 
No meds (n = 15), Losec (n=1), 
celexa (n=1), Cozaar & 
Lorazepam (n=1), Trazodone, 
Singluair & Cipralex (n=1) 
 
Health Status Healthy 
Healthy, fibromyalgia & 
rheumatoid arthritis (n=1), 
asthma (n=1) 
 
Height (cm) 172 (± 7.7) 168 (± 8.3)  
Weight (kg) 69 (± 15.9) 76 (± 14.1)  
* indicates significantly different from young, p<0.05 
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For the CVD state comparison, no data was statistically non-normal as assessed Mahalanobis 
distance scores. Box’s equality of covariance matricies test was not statistically significant. A 
significant MANOVA, F(24,108)=3.114, p<0.001, partial η2=0.409 was found. Shapiro Wilks’ W 
was significant for the height variable for the old group, and Levene’s test was significant for the 
age, SBP and Height measures, though due to the robustness of ANOVA with equal sample sizes, 
this is not a concern. All dependent variable ANOVAs were statistically significant for the 
following variables: 
 Age -- F(4,29)=29.738, p<0.001, partial η2 = 0.804 
 SBP -- F(4,29) = 3.148, p=0.029, partial η2 = 0.303 
 DBP -- F(4,29) = 4.055, p=0.010, partial η2 = 0.359 
Tukey’s HSD post hoc indicated the significant differences presented in Table 9. * 
indicates different from young, ‡ indicates different from CHF. There were no statistical 
differences between Old, Met and CAD groups. A bonferroni correction was not applied 
to this comparison as these results were used for streamlining the variables to be 
further assessed and were not used as a final reported value. Appendix D contains a 
table with full descriptive statistics on the CVD state comparison. 
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Table 9: Mean Young, Old, Metabolic Syndrome, Coronary Artery Disease and Chronic Heart 
Failure Anthropometric, Vitals and Health Status Data - Cardiovascular Disease Comparison (* = 
different from young, ‡ = different from CHF). 
 
Young          
(± SD) 
Old             
(± SD) 
Metabolic 
Syndrome     
(± SD) 
Coronary 
Artery 
Disease (± SD) 
Chronic Heart 
Failure            
(± SD) 
Statistical 
Difference 
n 7 7 7 7 6  
Age (years) 
27        
(± 3.9) 
62 *       
(± 11.0) 
60 * (± 5.6) 69 * (± 7.0) 61 * (± 9.1) 
All groups, 
p<0.001 
Sex (M:F) 3:4 5:2 3:4 4:3 3:3  
SBP (mmhg) 
113      
(± 13.8) 
137      
(± 16.6) 
120 (± 9.2) 135 (± 24.5) 137 (± 9.6) 
 
DBP (mmhg) 
68 ‡        
(± 9.2) 
72 ‡       
(± 8.8) 
76 (± 9.3) 73  (± 8.9) 87 * (± 7.9) 
Y: p=0.006, 
O: p=0.039, 
CHF: 
p=0.006 
RHR (bpm) 
63        
(± 8.8) 
57        
(± 3.6) 
68 (± 6.2) 58 (± 10.5) 63 (± 9.3) 
 
Medications 
BCP 
(n=2) 
None See below
1 
See below
2
 See below
3  
Health 
Status 
Healthy Healthy 
HTN (n=6), 
high 
cholesterol 
(n=6), high 
glucose (n=1) 
Healthy, 
smoker (n=1) 
Class I CHF 
(n=2) Class II 
CHF (N=4) 
 
Height (cm) 
175      
(± 4.8) 
167      
(± 4.4) 
167 (± 9.7) 170 (± 9.0) 168 (± 12.4) 
 
Weight (kg) 
77        
(± 17.2) 
72 
(13.6) 
94 (± 17.3) 85 (±18.2) 84 (± 19.3) 
 
1
 Met Medications (n=1 unless specified): statins (n=4), anti-platelet agents, antidepressants, lipid lowering agent, 
ACE inhibitors, Ca
2+
 channel blockers, diuretic (n=2), proton pump inhibitors (n=2), antidiabetic, benzodiazepines 
(n=2), angiotensin receptor blockers (n=2) 
 
2 
CAD Medications (n=1 unless specified): Beta-blockers (n=5), statins (n=7), anti-platelet agents (n=7), anti-
depressants, ACE inhibitors (n=6), Ca
2+
 channel blocker, selective estrogen receptor modulator, proton pump 
inhibitor, thyroid hormone replacement, nitroglycerine (n=3) 
3 
CHF Medications (n=1 unless specified): Diuretic (n=6), ACE inhibitor (n=5), Beta Blockers (n=5), aldosterone 
receptor antagonists (n=2), anti-platelet agents (n=2), anti-arrhythmic, potassium, antihypertensive 
Physiology Methods 
In addition to recording data for 3 young subjects for an original study conducted 
by the author, files from the neurovascular research lab database were extracted for 
the group comparisons in this study. The data were recorded at Western University to 
the exception of all the CHF data which was obtained via a study at the University Of 
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Split School Of Medicine in Croatia. Ethics approval for all studies from which data was 
used are included in Appendix H. All research methods were approved by the ethics 
review board at the university where each recording took place. Research methods 
were explained to all participants who gave their informed consent to participate in 
research both orally and in writing prior to commencing the experimental trials. All 
raw MSNA data were labelled and analysed by the author. 
MSNA Recording 
In all cases, after obtaining informed consent, baseline MSNA recordings were 
made while the participant was lying in the supine position from the peroneal nerve 
posterior to the fibular head. A reference electrode was positioned subcutaneously 1-
3cm from the recoding site. The active recording site consisted of a tungsten 
microelectrode (35mm long, 200μm in diameter, and tapered to a 1-5μm uninsulated 
tip) inserted percutaneously by a trained microneurographer. The microelectrode was 
manipulated until an appropriate MSNA site was found and confirmed as muscle 
sympathetic (see Isolating Muscle- from Cutaneous-Nerve Bundles.) through the 
presence of a characteristic pulse-synchronous burst pattern in the integrated 
neurogram, response to voluntary apnea but not startle, as well as absence of skin 
paresthesia (Steinback et al., 2010). The MSNA neurogram was amplified 1000X 
through a pre-amplifer and 75x by a variable-gain, isolated amplifier. This amplified 
raw signal was then bandpass filtered at 700-2000Hz, to form the filtered signal and 
then rectified, integrated and sampled at 10 000Hz to form the integrated signal and 
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stored offline for further analysis (Powerlab software, ADInstruments Inc., Colorado 
Springs, CO, USA).  
Baseline data were recorded for 1-5minutes in all subjects, and files with a signal 
to noise ratio (SNR) of >3 were selected for subsequent AP analysis. Sympathetic 
bursts were manually identified and marked on the integrated neurogram in the 
original labchart file. Segments of interest were then exported for AP analysis with our 
AP detection program. A 15s sample of raw ECG, BP and MSNA (filtered and integrated 
neurograms) data from an average young and old participant is displayed in Figure 20. 
Raw samples from the CVD state comparison are also displayed in the following 
figures: Figure 21 - young, Figure 22- old, Figure 23- Met, Figure 24- CAD, and Figure 
25- CHF. 
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Figure 20: Baseline ECG, BP and MSNA data from (A) an average Young Participant (Male, age: 23, HR: 55bpm, latency: -1.36s) and (B) an 
average Old Participant (Male, age: 61, HR: 55bpm, latency: -1.21s) in the age-based comparison               
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Figure 21: Baseline ECG, BP and MSNA data from an average Young Participant (Male, age: 25, HR: 
64bpm, latency: -1.36s) in the CVD state-based Comparison
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Figure 22: Baseline ECG, BP and MSNA data from an average Old Participant (Female, age: 60, HR: 
58bpm, burst latency: -1.23s) in the CVD state-based Comparison 
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Figure 23: Baseline ECG, BP and MSNA data from an average Met Participant (Male, age: 58, HR: 
72bpm, burst latency: -1.22s) in the CVD state-based Comparison 
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Figure 24: Baseline ECG, BP and MSNA data from an average CAD Participant (Male, age: 67, HR: 
47bpm, burst latency: -1.38s) in the CVD state-based Comparison 
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Figure 25: Baseline ECG, BP and MSNA data from an average CHF Participant (Female, age: 61, HR: 
50bpm, burst latency: -1.17s) in the CVD state-based Comparison
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Action Potential Detection  
APs were detected and extracted from the filtered MSNA neurogram using a novel 
matlab-based program developed in our lab (Salmanpour et al., 2010). Analysis was 
limited to 800ms sections of data surrounding the “burst” labels applied to the raw lab 
chart files to ensure that APs captured were representative of APs found within bursts. 
To describe the analysis procedure briefly, a mother wavelet matched to the average 
post-ganglionic sympathetic AP shape is applied to the data as a continuous wavelet 
transform (CWT) to produce a wavelet coefficient (Salmanpour et al., 2010). The 
coefficient is high in the presence of a matching AP shape and negligent with noise, 
enabling their separation via thresholding. Detected APs are then extracted from the 
filtered signal, thereby preserving their morphology, and can be clustered in terms of 
their peak-to-peak amplitude. Spikes (individual APs) or clusters may then be used to 
quantify MSNA in terms of AP firing frequency (time), incidence (per 100 heart beats) or 
integrated bursts. Previously, this program has been used to look at AP recruitment 
patterns in reflex-mediated responses (Breskovic, Steinback, Salmanpour, Shoemaker, & 
Dujic, 2011; Steinback et al., 2010; Zubin Maslov, Breskovic, Brewer, Shoemaker, & 
Dujic, 2012). In this study, use of AP detection was aimed at understanding baseline 
characteristics rather than recruitment patterns and determining whether this AP-based 
information could be used to distinguish between groups of varying age and CVD health 
status. Mean and standard deviation values of physiological parameters for all groups 
are shown in Table 10 (age comparison) and Table 12 (CVD state comparison). Full 
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descriptive statistics on these measures may be found in Appendix E and Appendix F for 
the Age and CVD state comparisons respectively.  
Statistical Methods 
MSNA data analysis yields several parameters which may be used to describe or 
quantify MSNA as a whole. For both studies the following variables were collected and 
subsequently assessed: burst raw amplitude (v), burst latency (s), mean burst area (v/s), 
mean burst area per min (v/s2), burst frequency (bursts/min), burst incidence 
(bursts/100hb), mean spikes per burst, spikes per min, spikes per 100hb, and clusters 
per burst. All statistical comparisons were made using SPSS statistics software (IBM, 
New York, USA). SPSS syntax used for this study may be found in Appendix B.  
MANOVA Methods 
Initially, all variables were entered to produce descriptive statistics on the data set 
and check for outliers based on mahalanobis distance scores.  Any outliers were 
removed from the sample and the process was repeated until no outliers remained. As 
explained in chapter 2, mahalanobis distance scores are compared to a chi-square value 
(evaluated at p=0.001) for a given set of degrees of freedom based on the number of 
dependent variables used (n-1).  The MANOVA was then completed with all variables 
included (to the exception of age). Univariate ANOVAs followed to examine individual 
contributions of each variable to the tests’ variability. In the case that the comparison 
made between >2 groups, as in the CVD state comparison, a tukey’s HSD post hoc was 
applied to significant ANOVAs to determine where differences between groups existed. 
Subsequently, correlations between significantly different variables, as determined in 
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the MANOVA and univariate ANOVAs, were completed. Variables containing amplitude-
based values were eliminated at this stage. In both cases, burst frequency and incidence 
along with spikes/min and /100hb were the only statistically significant variables 
remaining after this step. These four variables were indeed correlated and deemed to 
be physiologically relevant in describing MSNA by the author and were carried forward 
for a modified step-down approach through the use of MANCOVA. This MANCOVA 
assessed the variability between groups attributable to both burst frequency and 
incidence alone while accounting for the variability attributable to spikes/min and 
spikes/100hb. The results of this statistical examination are presented in the following 
section. 
Results 
The results from the current experiment have been split into two sections to 
adequately explain findings for both the age and CVD comparisons. These results will be 
discussed in detail in chapter 4. 
Age Comparison (young vs old) 
Using the 10 quantified MSNA variables, a MANOVA was conducted to determine 
differences between age-based groups. Box’s M test for equality of covariance matrices 
was significant though considering the equal sample sizes used in the comparison, the 
effects of this significance are minimal (Hakstian et al., 1979). Additionally, Levene’s test 
of equality of error variances was significant for mean burst area/min, and burst 
frequency though again, MANOVA is robust to violations of variance when sample sizes 
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are equal. Lastly, the Shapiro-Wilk W test for normality was significant (p<0.05) for the 
following variables assessed for the young group: Burst raw amplitude, mean burst area, 
spikes/burst, spikes/min, spikes/100hb, clusters/burst and age, and for the old group: 
spikes/100hb. With equal sample sizes, MANOVA is robust to violations of normality 
(Mardia, 1971). As such, the test continued without modification of the raw data. 
MANOVA 
Pillai’s Trace indicated a statistically significant MANOVA, F (10,26) = 5.374, p<0.05, 
partial eta-square = 0.674. This indicates that age differences account for 67.4% of the 
variability within the canonical variate assessed by the MANOVA. Subsequent ANOVAs 
were performed to determine the univariate contributions of each variable to the 
variability accounted for by age. These values are depicted in Table 10. Only statistically 
significant comparisons between the groups are presented. These values illustrate the 
extent to which there is a statistically significant effect of each individual variable 
without accounting for correlations between them. As evidenced in 
Table 10, statistically significant comparisons were made for mean burst area/min, 
burst frequency, burst incidence, spikes/min and spikes/100hb.  Of specific note are the 
effect size estimates, or partial η2 values, for each significant comparison which denote 
the amount of variability in the difference attributed to age. Specifically, in comparing 
partial η2 values for burst frequency and incidence with spikes/min and spikes/100hb, it 
should be noted that effect size estimates for spike variables, equating to a moderately 
sized ~0.6 power, are considerably smaller than their integrated variable counter parts 
which equate to a large sized ~0.99 power. Since mean burst area/min contains an 
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amplitude measure which cannot be reliably compared between groups it was excluded 
from further analysis.  
Table 10: Mean and Standard Deviation values for Age Comparison Physiological Data  
Variable Group Mean St. Dev Statistical Comparison 
Burst Raw Amp 
Young .186 .067  
Old .181 .058  
Burst Latency 
Young -1.24 .08  
Old -1.26 .07  
Mean Burst Area 
Young .058 .019  
Old .057 .018  
Mean Burst Area/min 
Young 1.133 .6179 F(1,35) = 12.13, p = 0.001, 
partial η
2
 = 0.257 Old 2.152 1.085 
Burst Frequency 
Young 18.9 6.2 F(1,35) = 28.47, p < 0.001, 
partial η
2
 = 0.449 Old 37.4 13.4 
Burst Incidence 
Young 31.4 10.2 F(1,35) = 43.69, p < 0.001, 
partial η
2
 = 0.555 Old 61.2 16.3 
Spikes /burst 
Young 9.7 7.5  
Old 9.1 4.3  
Spikes /min 
Young 199.9 197.5 F(1,35)= 5.11, p = 0.03, 
partial η
2
 = 0.127 Old 358.8 227.9 
Spikes /100hb 
Young 324.4 300.2 F(1,35) = 5.68, p = 0.023, 
partial η
2
 = 0.140 Old 587.6 366.1 
Clusters /burst 
Young 4.7 2.6  
Old 5.1 2.0  
* indicates significant difference from young group. F-values, significance level and effect size values 
are noted for significant comparisons (p <0.05) 
In interpreting the above results, the question of which time and heart beat related 
parameters, burst or spike, account for the most variability in the comparison arises. 
These variables are correlated with each other, all at a two-tailed p< 0.01 level as 
displayed in Table 11.  
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Table 11: Age-based correlations between burst and spike parameters 
  Spikes/min Spikes/100hb 
Burst 
Frequency 
Pearson Correlation .704 .638 
Sig. (2-tailed) .000 .000 
N 37 37 
Burst 
Incidence 
Pearson Correlation .673 .692 
Sig. (2-tailed) .000 .000 
N 37 37 
As such, the subsequent analysis consisted of a second multivariate analysis aimed 
at determining the variability associated with burst frequency and incidence alone while 
accounting for the variability associated with spikes/min and spikes/100hb through a 
MANCOVA. The ordering of these parameters was intentionally decided as burst 
parameters have stronger representation and understanding expressed in the literature 
and spike parameters, though they are the fundamental units creating burst 
parameters, are a new approach to MSNA analysis. 
MANCOVA 
For the second analysis, a MANCOVA was performed to determine whether burst 
variables significantly distinguish between groups after controlling for correlated spike 
variables. Box’s M test of equality of covariance matrices was significant at p<0.001, but 
as in the first MANOVA, sample sizes are equal which makes the analysis robust to this 
violation (Hakstian et al., 1979). Levene’s test of equality of error variances was not 
significant. Again, Shapiro-Wilks W test was significant for the young group spikes/min 
and spikes/100hb, though the test is robust to this type of violation given equal sample 
sizes (Mardia, 1971). 
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A significant MANCOVA was found using Pillai’s trace F(2, 32) = 17.945, p<0.05, 
partial η2=0.529. This suggests that the burst frequency and incidence variables can 
discriminate between young and old groups even after removing the effects of 
spikes/min and spikes/burst variables. In this comparison, age differences account for 
52.9% of the variability within the combined burst frequency and incidence variables. 
Cardiovascular Disease State Comparison (Young, Old, Met, CAD, CHF) 
The same ten variables were examined for the CVD state comparison using the same 
statistical methods as the age comparison above. The Shapiro-Wilk W test of normality 
indicated non normality for the following groups and variables: Old – mean burst area, 
Met – spikes/100hb, clusters/burst, CAD – burst latency, and CHF – burst raw amplitude, 
mean burst area/min, all p<0.05. MANOVA is however robust to this type of normality 
violation when sample sizes are equal (Mardia, 1971), thus no modifications were made 
to the data. Additionally, Levene’s test of equality of error variances was significant for 
the following variables: burst raw amplitude, burst latency, mean burst area/min, 
spikes/min and spikes/100hb. As mentioned, MANOVA is robust against violations of 
variance when sample sizes are equal (Hakstian et al., 1979), thus the analysis continued 
despite the violations. 
MANOVA 
 A statistically significant MANOVA was calculated using Pillai’s Trace, F(40, 92) = 
2.064, p = 0.002, partial η2 = 0.473. This suggests that when using all variables to predict 
differences between groups that CVD state accounts for 47.3% of the variability within 
the canonical variate assessed by the MANOVA. Like in the age comparison, this 
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MANOVA was followed by a series of univariate ANOVAs with Tukey’s HSD post hocs 
(for significant ANOVAs) to ascertain the extent to which there is a statistically 
significant effect for each individual variable, without considering correlations with 
other variables. Calculated ANOVAs were found to be significant for the following 
variables:  
 burst raw amplitude -- F(4,29) = 5.724, p=0.002, partial η2 = 0.441, 
 mean burst area -- F(4,29) = 4.902, p=0.004, partial η2 =0.403, 
 mean burst area/min -- F(4,29) = 9.438, p<0.001, partial η2 =0.566, 
 burst frequency -- F(4,29) = 10.418, p<0.001, partial η2 =0.590, 
 burst incidence -- F(4,29) = 10.972, p<0.001, partial η2 = 0.602 
 spikes/min -- F(4,29) = 3.305, p=0.024, partial η2 = 0.313 
 spikes/100hb -- F(4,29) = 3.148, p=0.029, partial η2 = 0.303 
Effect size estimates, or partial η2 values equate to power ranging from 0.77 (partial 
η2=0.303) to 1 (partial η2=0.602). Significant differences from young (*) and CHF (‡) 
groups for each variable are noted in Table 12 along with mean and standard deviations 
by group, all p<0.05. There were no significant differences between old, Met and CVD 
mean values on any variable. 
 
Table 12: Mean and Standard Deviation values for CVD state Comparison Physiological Data 
denoting significant differences from young (*) and CHF (‡) groups.  
Variable Group Mean St. Dev Significant Differences 
Burst Raw Amp 
young .224 .067  
old .154 .028 ‡ p=.001 
Met .194 .029 ‡ p=.020 
CAD .199 .061 ‡p=.028 
CHF .295 .076  
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Burst Latency 
young -1.23 0.08  
old -1.26 0.09  
Met -1.25 0.06  
CAD -0.58 1.23  
CHF -1.23 0.08  
Mean Burst Area 
young .067 .019  
old .050 .010 ‡ p=.002 
Met .061 .009 ‡ p=.028 
CAD .061 .018 ‡ p=.031 
CHF .092 .029  
Mean Burst 
Area/min 
young 1.369 .684 ‡ p<.001 
old 1.887 .784 ‡ p<.001 
Met 2.148 .639 ‡ p=.001 
CAD 2.113 .862 ‡p=.001 
CHF 4.993 2.258  
Burst Frequency 
young 20.1 7.0 ‡ p<.001 
old 37.4 11.6 * p=.012; ‡ p=.037 
Met 36.0 9.6 * p=.024; ‡ p=.019 
CAD 34.1 8.1 ‡ p=.008 
CHF 53.0 9.0 * p<.001 
Burst Incidence 
young 33.0 13.4 ‡ p<0.001 
old 65.6 16.6 * p=.002 
Met 55.3 16.6 ‡ p=.007 
CAD 59.4 14.3 * p=.017; ‡ p=.024 
CHF 85.7 10.9 * p<.001 
Spikes /burst 
young 10.6 6.6  
old 9.0 3.8  
Met 9.8 3.3  
CAD 8.9 3.0  
CHF 12.3 7.6  
Spikes /min 
young 207.6 116.2 ‡ p=.015 
old 349.1 215.4  
Met 327.2 88.6  
CAD 298.7 105.0  
CHF 695.7 536.7 * p=.015 
Spikes /100hb 
young 339.3 194.7 ‡ p=.018 
old 613.9 367.0  
Met 480.4 149.2  
CAD 527.1 206.7  
CHF 1094.7 820.9 * p=.018 
Clusters /burst 
young 5.1 1.9  
old 5.3 1.8  
Met 5.0 1.3  
CAD 4.9 0.7  
CHF 6.2 2.6  
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Eliminating all significant variables which have an amplitude component again leaves 
Burst Frequency and Incidence as well as Spikes/min and Spikes/100hb as significantly 
discriminating between groups on their own. These variables again are correlated with 
each other as seen in Table 13, all p<0.001, two-tailed. 
Table 13: Correlations between Burst Frequency and Incidence with Spikes/min and Spikes/100hb 
 
Spikes/min Spikes/100hb 
Burst 
Frequency 
Pearson Correlation .699 .672 
Sig. (2-tailed) .000 .000 
N 34 34 
Burst 
Incidence 
Pearson Correlation .623 .655 
Sig. (2-tailed) .000 .000 
N 34 34 
MANCOVA 
As in the age comparison, the next step in the analysis was to conduct a MANCOVA 
to determine the variability attributed to burst frequency and incidence together with 
the effects of spikes/min and spikes/100hb given their significant correlation.  
For this test, neither Box’s test of equality of covariance matrices or Levene’s test of 
equality of error variances were statistically significant indicating homogeneous variance 
between groups. As in the first MANOVA on this data set, Shapiro-Wilk W tests 
suggested non-normality in the spikes/100hb for the Met group. Again, this test is 
robust against normality violations (Mardia, 1971). 
Pillai’s trace indicated a significant MANCOVA, F(8,54) = 2.300, p=0.034, partial η2 = 
0.254. This suggests that accounting for the effects of spikes/min and spikes/100hb, 
burst frequency and incidence together can significantly differentiate between groups of 
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differing CVD state, with CVD state accounting for 25.4% of the variance associated with 
the group difference. 
Summary 
To summarize, multivariate statistical tests were used on two data sets, age and CVD 
state comparisons, to evaluate a canonical variate comprised of 10 MSNA variables. In 
both cases, excluding variables involving burst amplitude measures, burst frequency, 
burst incidence, spikes/min and spikes/100hb were significantly different between 
groups as assessed by univariate ANOVAs. These variables were found to be correlated 
significantly with each other. As such, the subsequent MANCOVA analysis was 
completed to separate the variability associated with burst and spike parameters from 
each other. In both cases, burst frequency and incidence together were able to 
significantly differentiate between groups with the effects of spikes/min and 
spikes/100hb accounted for. Chapter 4 will discuss these findings in detail, particularly 
with regards to physiological impact, recording recommendations and study limitations. 
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Chapter 4 
Discussion & Conclusion 
The key findings of this study were that integrated burst characteristics, specifically 
burst frequency and incidence, account for the most variability attributed to a group 
difference (age or CVD state) at baseline, in comparison to other MSNA variables. This 
did not support the original hypothesis that newly available action potential (AP) MSNA 
variables would better discriminate between groups of varying age and CVD state in 
comparison to traditional integrated MSNA variables at baseline.  
These findings suggest that traditional methods of integrated MSNA analysis, 
including burst frequency and incidence may be used to adequately describe differences 
between groups of varying age and CVD state at baseline. In comparing burst frequency 
and incidence values across age-based groups at baseline, the results of this study 
suggest that Young < Old in both measures. For the CVD-state based comparison in 
terms of burst frequency, Young < Old, Met and CHF, CAD = Young, Old, and Met and 
CHF > all other groups. In terms of bursts incidence in the CVD state comparison, Young 
< Old, CAD and CHF, Met = Young, Old and CAD, and CHF > all other groups. These 
results suggest that individuals of varying age have age-related characteristic baseline 
burst frequency and incidence levels, which are not further impacted by CVD state until 
a severe state (CHF). Regarding AP data, it is possible that APs fire in a similar fashion 
across groups at baseline regardless of age and CVD state until a severe disease state 
(CHF) is reached, as evidenced in the CVD state comparison suggesting AP differences in 
terms of spikes/min and spikes/100hb between Young and CHF groups only. An age-
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related difference was not noted for AP parameters in the CVD state comparison, but 
was present in the age-based comparison likely due to a power issue in the age-based 
comparison where the power for spikes/min and spikes/100hb were 0.60 and 0.64 
respectively (p=0.05, n=18 and 19 -- computed using g-power 3.1, Heinrich Heine 
Universitӓt Düsseldorf, Institut für Experimentelle Psychologie) suggesting a moderate 
effect. Thus we cannot state with confidence, despite a statistically significant and 
powerful MANOVA, that a type II error was not committed in comparing AP parameters 
in the age-based scenario, and that an age-related difference in AP variables exists. 
Actual AP recruitment strategies, which impact AP measures, may influence these 
outcomes under reflex-mediated responses. 
Though other studies have examined properties of MSNA variables and have made 
suggestions on standardizing the units and types of measures presented across the field 
(Guild et al., 2010; Malpas & Ninomiya, 1992), and on techniques used for determining 
SNA (Grassi & Esler, 1999; Macefield et al., 1994; Salmanpour, Brown, & Shoemaker, 
2008b), none of the previous studies have included AP measures and quantitatively 
determined the contributions of all measured variables to determine variability 
attributions and made conclusions based on those findings. 
Next Steps 
The main objective of this study was to examine group differences at baseline, and 
as such, work remains to be done regarding variable contributions to assessing group 
differences in a reflex-mediated response. AP recruitment patterns have been shown to 
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vary between control and apnea divers during breath holds (chemoreflex stress) in 
terms of AP/burst, clusters/burst, as well as integrated burst parameters including burst 
frequency, incidence and total MSNA (Breskovic et al., 2011). Additionally, premature 
ventricular contractions (Zubin Maslov et al., 2012) and high intensity (-80 mmHg) lower 
body negative pressure (LBNP - baroreflex stress) promotes the recruitment of a 
subpopulation of large APs with smaller latencies that are otherwise silent (Salmanpour 
et al., 2011). Together, these studies suggest that AP parameters may provide an 
effective means for assessing group differences during reflex-mediated responses, 
especially since integrated variables are unable to measure these changes in activity. 
Baroreflex regulation of burst frequency (occurrence) and amplitude (strength) of 
MSNA are differentially controlled (Kienbaum et al., 2001). Thus, measurements of burst 
frequency alone may fail to account for differences in burst amplitude related to the 
number and amplitude of individual spikes in the filtered signal (Delius, Hagbarth, 
Hongell, & Wallin, 1972). In this study, amplitude measures were eliminated from 
analysis after the initial multivariate group comparison on the concept of the influence 
of unknown electrode placement on the measured signal. Despite the ongoing 
controversy with assessing inter-individual differences in amplitude measures, 
amplitude components of the MSNA signal should be included in group comparisons in 
some capacity, especially in reflex-mediated response conditions. Work has been done 
regarding amplitude normalization in terms of total MSNA (burst frequency X mean 
absolute burst amplitude) (Mark, Victor, Nerhed, & Wallin, 1985), normalizing to 
maximum or average baseline responses (Kimmerly et al., 2004), and normalizing to 
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condition (Diedrich et al., 2009),  though more research regarding amplitude 
comparisons between groups must be done to establish an effective protocol for this 
type of inter-individual amplitude-based comparison. 
Limitations 
Though this study focussed on a total of 10 MSNA variables derived from the 
integrated and filtered neurograms, there are other representations of sympathetic 
nerve activity which were not included. These “other” variables represent both ones 
that have been quantified in the past (eg. plasma NE spillover), and ones that have yet 
to be discovered. As a result, the initial MANOVA, which was designed to assess MSNA 
as an overall concept, may be missing valuable parameters which help to distinguish 
more adequately between groups in comparison to burst frequency and incidence. As 
such, as more variables are discovered and measured, this process will have to be 
repeated to ensure that variables reported represent the best-case scenario for 
depicting group differences.  
From a physiological standpoint, finding that integrated MSNA measures adequately 
distinguish between groups at baseline makes conceptual sense in that individual spike 
parameters, albeit smoothed considerably, are what create the integrated signal. 
However, due to the nature of the generalized field recording of indeterminate size and 
location that MSNA represents, a direct causal relationship between MSNA variable 
values and vascular response cannot be drawn as a neural recording site cannot be 
linked directly to a specific vessel where a vasoconstrictor response could be measured. 
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It is important to consider which aspects of the MSNA signal the vessel responds best to, 
though without a way to establish a definitive link between neural and vascular 
recording sites, direct physiological implications are speculation.  Thus, though this 
study aimed at understanding which variables quantifiably contribute most to group 
separation may give researchers clues regarding variable physiological importance, it 
cannot confirm it. 
Conclusions & Recommendations 
Given the results of this study, both burst frequency and incidence should be 
reported for all baseline MSNA group or inter-individual comparisons as they account 
for the greatest amount of variability seen in a statistically significant group-based 
difference. Reflex-mediated responses were not assessed in this study, though AP MSNA 
measures in addition to traditional integrated measures should be reported under this 
circumstance until further research establishing separating variables in a reflex scenario 
has been completed. Comparisons of amplitude or amplitude-derived measures 
between groups should be normalized to account for the effects of the active electrode 
recording location and included in describing MSNA to some extent. Lastly, further work 
must be completed using this technique on reflex-mediated responses and in 
determining the role of amplitude-based MSNA measures in differentiating between 
groups. 
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Appendix A: Critical F-Values for p=0.05 
 
  
Treatment df 
  
Er
ro
r 
d
f 
 
1 2 3 4 5 6 7 8 9 10 
1 161.45 199.50 215.71 224.58 230.16 233.99 236.77 238.88 240.54 241.88 
2 18.51 19.00 19.16 19.25 19.30 19.33 19.35 19.37 19.39 19.40 
3 10.13 9.55 9.28 9.12 9.01 8.94 8.89 8.85 8.81 8.79 
4 7.71 6.94 6.59 6.39 6.26 6.16 6.09 6.04 6.00 5.96 
5 6.61 5.79 5.41 5.19 5.05 4.95 4.88 4.82 4.77 4.74 
6 5.99 5.14 4.76 4.53 4.39 4.28 4.21 4.15 4.10 4.06 
7 5.59 4.74 4.35 4.12 3.97 3.87 3.79 3.73 3.68 3.64 
8 5.32 4.46 4.07 3.84 3.69 3.58 3.50 3.44 3.39 3.35 
9 5.12 4.26 3.86 3.63 3.48 3.37 3.29 3.23 3.18 3.14 
10 4.97 4.10 3.71 3.48 3.33 3.22 3.14 3.07 3.02 2.98 
15 4.54 3.68 3.29 3.06 2.90 2.79 2.71 2.64 2.59 2.54 
20 4.35 3.49 3.10 2.87 2.71 2.60 2.51 2.45 2.39 2.35 
25 4.24 3.39 2.99 2.76 2.60 2.49 2.41 2.34 2.28 2.24 
30 4.17 3.32 2.92 2.69 2.53 2.42 2.33 2.27 2.21 2.17 
35 4.12 3.27 2.87 2.64 2.49 2.37 2.29 2.22 2.16 2.11 
40 4.09 3.23 2.84 2.61 2.45 2.34 2.25 2.18 2.12 2.08 
45 4.06 3.20 2.81 2.58 2.42 2.31 2.22 2.15 2.10 2.05 
50 4.03 3.18 2.79 2.56 2.40 2.29 2.20 2.13 2.07 2.03 
60 4.00 3.15 2.76 2.53 2.37 2.25 2.17 2.10 2.04 1.99 
70 3.98 3.13 2.74 2.50 2.35 2.23 2.14 2.07 2.02 1.97 
80 3.96 3.11 2.72 2.49 2.33 2.21 2.13 2.06 2.00 1.95 
90 3.95 3.10 2.71 2.47 2.32 2.20 2.11 2.04 1.99 1.94 
100 3.94 3.09 2.70 2.46 2.31 2.19 2.10 2.03 1.98 1.93 
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Appendix B: SPSS Syntax for Descriptive Statistics, MANOVA, Multivariate Outlier 
Determination, ANOVA, and MANCOVA 
 (Note: bolded text indicates what the syntax does and is not included in the syntax used to run the 
command in SPSS. Due to character limitations in SPSS, analysed variables were relabelled as outlined 
in the table below) 
In Text Variable SPSS Variable 
Burst Raw Amplitude burstrawamp 
Burst Latency burstlatency 
Mean Burst Area meanburstarea 
Mean Burst Area per Min mbapermin 
Burst Frequency burstfreq 
Burst Incidence burstincidence 
Spikes/burst spikesperburst 
Spikes/min spikespermin 
Spikes/100hb spikesper100 
Clusters/burst clusters/burst 
 
Descriptive Statistics 
EXAMINE VARIABLES=burstrawamp burstlatency meanburstarea mbapermin burstfreq 
burstincidence  
    spikesperburst spikespermin spikesper100 clustersperburst age BY group 
  /PLOT BOXPLOT STEMLEAF NPPLOT 
  /COMPARE GROUPS 
  /STATISTICS DESCRIPTIVES 
  /CINTERVAL 95 
  /MISSING LISTWISE 
  /NOTOTAL. 
 
Multivariate Outlier Detection (based on Mahalanobis Distance Scores) 
REGRESSION 
  /MISSING LISTWISE 
  /STATISTICS COEFF OUTS R ANOVA 
  /CRITERIA=PIN(.05) POUT(.10) 
  /NOORIGIN  
  /DEPENDENT group 
  /METHOD=ENTER burstrawamp burstlatency meanburstarea mbapermin burstfreq 
burstincidence  
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    spikesperburst spikespermin spikesper100 clustersperburst 
  /SAVE MAHAL. 
 
MANOVA followed by Univariate ANOVA with Tukey’s HSD post-hoc 
GLM burstrawamp burstlatency meanburstarea mbapermin burstfreq burstincidence 
spikesperburst  
    spikespermin spikesper100 clustersperburst BY group 
  /METHOD=SSTYPE(3) 
  /INTERCEPT=INCLUDE 
  /POSTHOC=group(TUKEY)  
  /PRINT=DESCRIPTIVE ETASQ HOMOGENEITY 
  /CRITERIA=ALPHA(.05) 
  /DESIGN= group. 
 
Checking Correlations between Burst Frequency, Burst Incidence, Spikes/min and 
Spikes/100hb 
CORRELATIONS 
  /VARIABLES=burstfreq burstincidence spikespermin spikesper100 
  /PRINT=TWOTAIL NOSIG 
  /STATISTICS DESCRIPTIVES 
  /MISSING=PAIRWISE. 
 
MANOVA using only burst frequency and incidence as dependent variables while 
accounting for variability associated with spikes/min and spikes/100hb 
GLM burstfreq burstincidence BY group WITH spikespermin spikesper100 
  /METHOD=SSTYPE(3) 
  /INTERCEPT=INCLUDE 
  /PRINT=DESCRIPTIVE ETASQ HOMOGENEITY 
  /CRITERIA=ALPHA(.05) 
  /DESIGN=spikespermin spikesper100 group.
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Appendix C: Descriptive Statistics - Age Comparison Anthropometric, Cardiovascular and Age Data  
Group 
Mean 
95% 
Confidence 
Interval Median Variance 
Std. 
Deviation 
Min Max Range IQR 
Skewness Kurtosis 
Stat 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Stat 
Std. 
Error 
Stat 
Std. 
Error 
Age 
young 24.2 0.8 22.4 25.9 23.0 12.1 3.5 19.0 33.0 14.0 4.0 1.259 0.54 1.696 1.04 
old 59.5 1.9 55.5 63.5 60.0 69.0 8.3 45.0 75.0 30.0 10.0 0.402 0.52 -0.45 1.01 
SBP 
young 111.9 3.0 105.6 118.2 108.0 160.4 12.7 96.0 139.0 43.0 19.5 0.728 0.54 -0.4 1.04 
old 124.1 4.1 115.5 132.6 125.0 312.7 17.7 100.0 168.0 68.0 20.0 0.791 0.52 0.81 1.01 
DBP 
young 66.8 2.0 62.6 71.1 66.5 74.0 8.6 57.0 85.0 28.0 11.5 0.95 0.54 0.352 1.04 
old 73.1 2.1 68.6 77.6 76.0 86.1 9.3 60.0 84.0 24.0 18.0 -0.24 0.52 -1.76 1.01 
RHR 
young 60.9 1.8 57.1 64.7 63.0 59.3 7.7 49.0 75.0 26.0 13.3 -0.14 0.54 -1.03 1.04 
old 60.7 2.7 55.1 66.3 58.0 134.6 11.6 42.0 97.0 55.0 9.0 1.736 0.52 4.764 1.01 
Ht 
young 171.9 1.8 168.1 175.7 174.5 59.4 7.7 158.5 183.0 24.5 14.5 -0.21 0.54 -1.36 1.04 
old 167.6 1.9 163.6 171.6 165.0 68.6 8.3 153.0 188.0 35.0 10.0 0.397 0.52 0.816 1.01 
Wt 
young 69.2 3.7 61.3 77.1 68.0 251.6 15.9 45.2 112.4 67.2 17.5 1.267 0.54 2.233 1.04 
old 76.5 3.2 69.7 83.3 80.7 197.8 14.1 52.3 97.5 45.2 20.7 -0.11 0.52 -0.97 1.01 
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Appendix D: Descriptive Statistics - Cardiovascular Disease State Comparison Anthropometric, Cardiovascular and Age Data  
Group 
Mean 
95% Confidence 
Interval  
Median Variance 
 Std. 
Deviation 
Min Max Range IQR 
Skewness Kurtosis 
Lower 
Bound 
Upper 
Bound Stat 
Std. 
Error 
Stat 
Std. 
Error 
Stat 
Std. 
Error 
Age 
young 26.9 1.5 23.3 30.5 26.0 15.1 3.9 22.0 33.0 11.0 7.0 .625 .79 -.609 1.59 
old 61.9 4.5 50.9 72.9 60.0 141.5 11.9 45.0 75.0 30.0 20.0 -.130 .79 -1.870 1.59 
met 60.0 2.1 54.8 65.2 59.0 31.7 5.6 50.0 67.0 17.0 6.0 -.715 .79 .625 1.59 
CAD 68.6 2.7 62.1 75.1 68.0 49.6 7.0 59.0 78.0 19.0 15.0 .182 .79 -1.000 1.59 
CHF 61.0 3.7 51.5 70.5 61.5 82.4 9.1 46.0 72.0 26.0 14.8 -.708 .85 .753 1.74 
SBP 
young 112.9 5.2 100.2 125.7 107.0 189.2 13.8 99.0 133.0 34.0 26.9 .574 .79 -1.690 1.59 
old 137.0 6.8 120.4 153.6 128.0 322.7 18.0 117.0 168.0 51.0 27.0 .879 .79 -.146 1.59 
met 120.6 3.5 112.0 129.1 121.0 85.3 9.2 107.0 132.0 25.0 18.0 -.479 .79 -1.077 1.59 
CAD 134.9 9.3 112.2 157.5 127.0 600.5 24.5 109.0 172.0 63.0 53.0 .630 .79 -1.039 1.59 
CHF 136.7 3.9 126.6 146.7 135.0 92.3 9.6 125.0 152.0 27.0 16.5 .665 .85 .115 1.74 
DBP 
young 68.2 3.5 59.7 76.8 67.0 85.0 9.2 59.0 84.6 25.6 16.0 1.002 .79 .281 1.59 
old 72.1 3.6 63.3 80.9 73.0 90.5 9.5 61.0 84.0 23.0 18.0 -.042 .79 -2.208 1.59 
met 73.6 3.5 64.9 82.2 72.0 88.0 9.4 58.0 86.0 28.0 13.0 -.457 .79 -.095 1.59 
CAD 73.0 3.4 64.8 81.2 72.0 79.0 8.9 63.0 87.0 24.0 16.0 .339 .79 -.869 1.59 
CHF 87.3 3.2 79.0 95.6 87.5 62.7 7.9 74.0 95.0 21.0 12.8 -.892 .85 .635 1.74 
RHR 
young 63.1 3.3 55.0 71.3 65.0 77.8 8.8 49.0 75.0 26.0 14.0 -.594 .79 -.193 1.59 
old 56.7 1.5 53.0 60.4 57.0 15.9 4.0 52.0 63.0 11.0 7.0 .404 .79 -.938 1.59 
met 67.1 2.4 61.4 72.9 66.0 38.8 6.2 59.0 77.0 18.0 10.0 .374 .79 -.672 1.59 
CAD 57.7 4.0 47.9 67.6 53.0 113.2 10.6 47.0 78.0 31.0 13.0 1.268 .79 1.461 1.59 
CHF 63.0 3.8 53.2 72.8 65.0 86.8 9.3 50.0 76.0 26.0 15.5 -.142 .85 -.515 1.74 
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Ht 
young 175.3 1.8 170.9 179.7 175.0 22.9 4.8 167.0 183.0 16.0 4.0 -.196 .79 1.993 1.59 
old 167.0 1.8 162.6 171.4 165.0 22.4 4.7 163.0 175.0 12.0 9.0 1.204 .79 -.325 1.59 
met 167.6 3.7 158.6 176.6 168.0 94.3 9.7 156.0 183.0 27.0 17.0 .306 .79 -.696 1.59 
CAD 170.1 3.4 161.8 178.5 175.0 81.1 9.0 157.0 178.0 21.0 18.0 -.631 .79 -1.778 1.59 
CHF 167.8 5.1 154.8 180.8 166.5 153.4 12.4 155.0 182.0 27.0 25.5 .160 .85 -2.633 1.74 
Wt 
young 76.8 6.5 60.9 92.7 71.5 296.0 17.2 60.0 112.4 52.4 16.5 1.786 .79 3.694 1.59 
old 72.0 5.5 58.4 85.5 66.2 214.2 14.6 52.3 97.5 45.2 17.7 .719 .79 .648 1.59 
met 96.6 6.5 80.6 112.6 90.0 298.6 17.3 80.0 128.0 48.0 27.0 1.296 .79 .590 1.59 
CAD 84.6 6.9 67.8 101.5 75.6 332.4 18.2 68.5 121.6 53.1 18.6 1.685 .79 2.927 1.59 
CHF 83.6 7.9 63.3 103.8 92.5 372.8 19.3 56.5 102.0 45.5 36.9 -.834 .85 -1.655 1.74 
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Appendix E: Descriptive Statistics - Age Comparison Physiological Data 
group 
Mean 
95% Confidence 
Interval for Mean 
Median Variance 
Std. 
Deviation 
Min Max Range IQR 
Skewness Kurtosis 
Stat 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Stat 
Std. 
Error 
Stat 
Std. 
Error 
Burst Raw 
Amp 
young .186 .016 .153 .219 .170 .004 .067 .110 .320 .210 .103 .795 .536 -.537 1.038 
old .181 .013 .153 .209 .170 .003 .058 .080 .300 .220 .070 .389 .524 -.117 1.014 
Burst 
Latency 
young -1.24 .02 -1.28 -1.20 -1.26 .01 .08 -1.36 -1.07 .29 .11 .57 .536 .04 1.038 
old -1.26 .02 -1.30 -1.23 -1.25 .01 .07 -1.44 -1.12 .32 .06 -.91 .524 1.88 1.014 
Mean Burst 
Area 
young .058 .005 .048 .067 .055 .000 .019 .034 .094 .060 .029 .651 .536 -.792 1.038 
old .057 .004 .048 .065 .054 .000 .018 .027 .091 .064 .014 .416 .524 -.009 1.014 
Mean Burst 
Area/min 
young 1.133 .146 .826 1.441 .990 .382 .6179 .40 2.74 2.34 .83 1.066 .536 1.147 1.038 
old 2.152 .249 1.629 2.675 1.990 1.178 1.0852 .62 4.46 3.84 1.77 .830 .524 .068 1.014 
Burst 
Frequency 
young 18.9 1.5 15.8 22.0 17.5 38.1 6.2 10.0 32.0 22.0 7.5 .7 .536 -.1 1.038 
old 37.4 3.1 30.9 43.9 34.0 180.8 13.4 14.0 72.0 58.0 14.0 1.0 .524 1.5 1.014 
Burst 
Incidence 
young 31.4 2.4 26.4 36.5 28.5 104.1 10.2 17.0 52.0 35.0 15.0 .7 .536 -.4 1.038 
old 61.2 3.7 53.3 69.0 59.0 264.8 16.3 24.0 96.0 72.0 24.0 .0 .524 .8 1.014 
Spikes 
/burst 
young 9.7 1.8 5.9 13.4 6.5 56.7 7.5 3.0 28.0 25.0 8.5 1.3 .536 .8 1.038 
old 9.1 1.0 7.0 11.2 8.0 18.8 4.3 3.0 20.0 17.0 6.0 1.1 .524 .8 1.014 
Spikes /min 
young 199.9 46.6 101.7 298.1 129.5 39010.1 197.5 32.0 816.0 784.0 247.0 2.0 .536 4.7 1.038 
old 358.8 52.3 248.9 468.7 338.0 51958.8 227.9 35.0 803.0 768.0 338.0 .6 .524 -.6 1.014 
Spikes 
/100hb 
young 324.4 70.8 175.1 473.7 217.0 90143.4 300.2 51.0 1191.0 1140.0 430.0 1.6 .536 2.9 1.038 
old 587.6 84.0 411.1 764.0 542.0 134027.5 366.1 60.0 1309.0 1249.0 365.0 .8 .524 -.2 1.014 
Clusters 
/burst 
young 4.7 .6 3.4 6.0 4.0 6.7 2.6 2.0 12.0 10.0 3.3 1.4 .536 2.4 1.038 
old 5.1 .5 4.1 6.1 5.0 4.0 2.0 2.0 9.0 7.0 2.0 .3 .524 -.6 1.014 
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Appendix F: Descriptive Statistics - Cardiovascular Disease State Comparison Physiological Data 
group 
Mean 
95% Confidence 
Interval for Mean 
Median Variance St. Dev Min Max Range IQR 
Skewness Kurtosis 
Stat 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Stat 
Std. 
Error 
Stat 
Std. 
Error 
Burst 
Raw Amp 
young .224 .025 .162 .287 .230 .005 .067 .150 .330 .180 .110 .373 .794 -1.142 1.587 
old .154 .010 .129 .180 .160 .001 .028 .100 .190 .090 .020 -1.224 .794 2.941 1.587 
Met .194 .011 .167 .221 .190 .001 .029 .150 .240 .090 .040 .184 .794 .088 1.587 
CAD .199 .023 .142 .255 .170 .004 .061 .140 .290 .150 .110 .599 .794 -1.658 1.587 
CHF .295 .031 .216 .374 .265 .006 .076 .240 .440 .200 .095 1.877 .845 3.615 1.741 
Burst 
Latency 
young -1.23 0.03 -1.31 -1.15 -1.22 0.01 0.08 -1.36 -1.11 0.25 0.11 -.219 .794 -.492 1.587 
old -1.26 0.03 -1.34 -1.18 -1.25 0.01 0.09 -1.41 -1.12 0.29 0.05 -.365 .794 2.436 1.587 
Met -1.25 0.02 -1.30 -1.20 -1.23 0.00 0.06 -1.33 -1.18 0.15 0.11 -.644 .794 -1.014 1.587 
CAD -0.58 0.46 -1.72 0.55 -1.24 1.51 1.23 -1.38 1.27 2.65 2.51 1.222 .794 -.830 1.587 
CHF -1.23 0.03 -1.31 -1.14 -1.19 0.01 0.08 -1.35 -1.16 0.19 0.15 -.961 .845 -1.321 1.741 
Mean 
Burst 
Area 
young .067 .007 .050 .085 .067 .000 .019 .047 .095 .048 .037 .307 .794 -1.550 1.587 
old .050 .004 .041 .059 .053 .000 .010 .030 .060 .030 .005 -1.793 .794 4.106 1.587 
Met .061 .003 .052 .069 .062 .000 .009 .044 .075 .031 .005 -.474 .794 2.595 1.587 
CAD .061 .007 .044 .078 .055 .000 .018 .043 .091 .048 .031 .725 .794 -.808 1.587 
CHF .092 .012 .062 .123 .084 .001 .029 .069 .147 .078 .040 1.730 .845 3.195 1.741 
Mean 
Burst 
Area 
/min 
young 1.369 .259 .736 2.001 1.270 .468 .684 .660 2.740 2.080 .650 1.505 .794 2.826 1.587 
old 1.887 .296 1.162 2.612 1.620 .615 .784 1.030 3.210 2.180 1.410 .825 .794 -.313 1.587 
Met 2.148 .242 1.557 2.739 2.002 .408 .639 1.270 3.039 1.769 1.201 .258 .794 -1.023 1.587 
CAD 2.113 .326 1.315 2.911 1.820 .744 .862 1.010 3.380 2.370 1.460 .385 .794 -1.265 1.587 
CHF 4.993 .922 2.624 7.362 3.975 5.097 2.258 3.430 9.380 5.950 2.748 2.000 .845 4.012 1.741 
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Burst 
Freq 
young 20.1 2.6 13.7 26.6 17.0 49.1 7.0 14.0 32.0 18.0 13.0 1.138 .794 -.358 1.587 
old 37.4 4.4 26.7 48.1 34.0 133.6 11.6 25.0 60.0 35.0 13.0 1.404 .794 2.150 1.587 
Met 36.0 3.6 27.1 44.9 38.0 93.0 9.6 22.0 51.0 29.0 15.0 .108 .794 -.230 1.587 
CAD 34.1 3.1 26.6 41.6 34.0 65.8 8.1 21.0 45.0 24.0 14.0 -.320 .794 -.122 1.587 
CHF 53.0 3.7 43.5 62.5 52.5 81.2 9.0 41.0 64.0 23.0 16.3 -.066 .845 -1.828 1.741 
Burst 
Incidence 
young 33.0 5.1 20.6 45.4 29.0 178.7 13.4 20.0 52.0 32.0 30.0 .665 .794 -1.375 1.587 
old 65.6 6.3 50.2 81.0 59.0 277.0 16.6 46.0 96.0 50.0 21.0 .983 .794 .902 1.587 
Met 55.3 6.3 40.0 70.6 57.0 274.9 16.6 35.0 86.0 51.0 19.0 .919 .794 1.370 1.587 
CAD 59.4 5.4 46.2 72.7 57.0 205.0 14.3 41.0 78.0 37.0 30.0 .264 .794 -1.434 1.587 
CHF 85.7 4.5 74.2 97.1 84.0 119.5 10.9 73.0 99.0 26.0 23.0 .290 .845 -1.865 1.741 
Spikes 
/burst 
young 10.6 2.5 4.5 16.6 7.0 43.0 6.6 5.0 22.0 17.0 11.0 1.118 .794 -.147 1.587 
old 9.0 1.4 5.5 12.5 8.0 14.7 3.8 5.0 16.0 11.0 6.0 1.122 .794 .752 1.587 
Met 9.8 1.2 6.7 12.8 9.0 10.8 3.3 6.0 14.0 8.0 7.0 .414 .794 -1.709 1.587 
CAD 8.9 1.1 6.1 11.6 9.0 8.8 3.0 5.0 14.0 9.0 4.0 .675 .794 .407 1.587 
CHF 12.3 3.1 4.4 20.3 10.5 57.9 7.6 4.0 26.0 22.0 10.8 1.292 .845 2.142 1.741 
Spikes 
/min 
young 207.6 43.9 100.1 315.1 147.0 13510.6 116.2 100.0 369.0 269.0 227.0 .476 .794 -2.158 1.587 
old 349.1 81.4 150.0 548.3 291.0 46381.5 215.4 114.0 698.0 584.0 398.0 .863 .794 -.625 1.587 
Met 327.2 33.5 245.3 409.1 309.0 7846.5 88.6 236.0 507.0 271.0 90.0 1.634 .794 3.144 1.587 
CAD 298.7 39.7 201.6 395.9 307.0 11031.9 105.0 180.0 461.0 281.0 198.0 .531 .794 -1.078 1.587 
CHF 695.7 219.1 132.4 1258.9 540.0 288065.9 536.7 175.0 1668.0 1493.0 791.0 1.421 .845 2.074 1.741 
Spikes 
/100hb 
young 339.3 73.6 159.3 519.3 275.0 37893.2 194.7 152.0 591.0 439.0 419.0 .405 .794 -2.111 1.587 
old 613.9 138.7 274.4 953.3 542.0 134717.1 367.0 213.0 1127.0 914.0 776.0 .757 .794 -1.144 1.587 
Met 480.4 56.4 342.4 618.4 450.5 22263.2 149.2 370.0 805.0 435.0 100.0 2.205 .794 5.338 1.587 
CAD 527.1 78.1 335.9 718.3 521.0 42742.5 206.7 271.0 890.0 619.0 312.0 .700 .794 .497 1.587 
CHF 1094.7 335.1 233.2 1956.2 757.0 673893.5 820.9 319.0 2595.0 2276.0 1133.0 1.523 .845 2.227 1.741 
Clusters 
/burst 
young 5.1 0.7 3.4 6.9 4.0 3.5 1.9 3.0 8.0 5.0 3.0 .577 .794 -1.334 1.587 
old 5.3 0.7 3.6 6.9 5.0 3.2 1.8 3.0 8.0 5.0 3.0 .368 .794 -1.130 1.587 
Met 5.0 0.5 3.8 6.2 4.0 1.7 1.3 4.0 7.0 3.0 2.0 .651 .794 -1.704 1.587 
CAD 4.9 0.3 4.2 5.5 5.0 0.5 0.7 4.0 6.0 2.0 1.0 .174 .794 .336 1.587 
CHF 6.2 1.0 3.5 8.9 6.0 6.6 2.6 3.0 10.0 7.0 4.8 .366 .845 -.571 1.741 
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Appendix G: Copyright Permissions for Figure and Table Reuse 
Figure 6 – Chapter 1 
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Figures 7 & 12 – Chapter 1 
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Figures 8 & 13 – Chapter 1 
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Figure 10 – Chapter 1 
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Figure 17 – Chapter 1 
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